var title_f30_32_31232="Xanthogranulomatous chol CT";
var content_f30_32_31232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Xanthogranulomatous cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of the abdomen in a patient with xanthogranulomatous cholecystitis showing a thickened gallbladder wall (arrow) with intramural hypodense nodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy Faripour Forouhar, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31232=[""].join("\n");
var outline_f30_32_31232=null;
var title_f30_32_31233="Cubitus valgus";
var content_f30_32_31233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cubitus valgus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) A 10-year-old boy with a right arm cubitus valgus (increased carrying angle with arm pointing farther away from the body in anatomic position) resulting from a fracture of the right lateral condylar physis with nonunion. B) Nonunion with cubitus valgus. Radiograph showing both angulation and translocation secondary to nonunion of the condylar fragment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beary JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31233=[""].join("\n");
var outline_f30_32_31233=null;
var title_f30_32_31234="Trichophyton skin test: Drug information";
var content_f30_32_31234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trichophyton skin test: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F12702460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F230839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diagnostic aid:",
"     </b>",
"     Intradermal: 0.1 mL, examine reaction site in 15-20 minutes; induration may also appear in 24-48 hours; sites showing a wheal or flare response should be scored based on mm reference scale",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F12704216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F230840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 1:200 (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F230835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clean skin with alcohol prior to administering (allow to dry completely). Administer by intradermal injection into volar surface of forearm and four rows on the back; do not administer I.V. Patients should be observed for 20 minutes following test and instructed to return to office or ER if signs or symptoms of allergic reaction occur.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Skin test in diagnosis of Type I hypersensitivity to",
"     <i>",
"      Trichophyton",
"     </i>",
"     fungus",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12704121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Bradycardia, hypotension, pallor, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioedema, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Cough, rhinitis, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Allergy exacerbated, anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12703288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extreme sensitivity to an allergen; recent myocardial infarction (MI); highly unstable asthma or unstable asthma in combination with beta-adrenergic blocker treatment",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Temporarily withhold in patients with severe symptoms of hay fever and/or asthma, infection or flu accompanied by fever, and excessive exposure to clinically relevant allergen prior to skin testing",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12704118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe reactions may occur (may be fatal); monitor for 20 minutes after testing; medications for the treatment of reactions should be available for immediate use.",
"     </b>",
"     Excessive local and systemic reactions are more possible during skin testing  in patients with recent contact with the allergen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Antihistamines/sympathomimetics: The use of antihistamines or sympathomimetics should be avoided for &ge;24 hours prior to skin testing; reactivity of the skin may be affected by these agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in administration of allergenic extracts.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Not for intravenous administration:",
"     <b>",
"      [U.S. Boxed Warning]: For intradermal administration only; do not administer intravenously.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F230829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12702461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. In normal pregnancies, cautious use is not expected to be harmful; however, due to the potential for histamine release to cause smooth muscle contraction, extensive testing should be avoided in pregnancy. Immunosuppressive changes during pregnancy may blunt the effects of skin testing. Avoid use in pregnancy unless clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12702462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F17918159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if",
"     <i>",
"      Trichophyton",
"     </i>",
"     skin test is excreted in breast milk. The manufacturer recommends that caution be exercised when administering",
"     <i>",
"      Trichophyton",
"     </i>",
"     skin test to nursing women.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10297 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31234=[""].join("\n");
var outline_f30_32_31234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12702460\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230841\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230839\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12704216\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230840\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230832\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230824\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230835\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230833\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12704121\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12703288\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12704118\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300171\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223459\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230829\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12702461\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12702462\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F17918159\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31235="Benzocaine, butamben, and tetracaine: Patient drug information";
var content_f30_32_31235=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Benzocaine, butamben, and tetracaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/19/41267?source=see_link\">",
"     see \"Benzocaine, butamben, and tetracaine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3033396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cetacaine&reg;;",
"     </li>",
"     <li>",
"      Exactacain&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691414",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzocaine, butamben, tetracaine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blue or gray skin color, headache, dizziness, trouble breathing, feeling tired or weak, and/or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696365",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will put on.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your eyes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11587 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31235=[""].join("\n");
var outline_f30_32_31235=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033396\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014964\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014963\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014968\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014969\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014971\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014966\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014967\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014972\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014973\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/19/41267?source=related_link\">",
"      Benzocaine, butamben, and tetracaine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31236="Diagnosis and management of gestational hyperandrogenism";
var content_f30_32_31236=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of gestational hyperandrogenism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31236/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31236/contributors\">",
"     Howard D McClamrock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31236/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31236/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31236/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31236/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31236/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/32/31236/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperandrogenism in pregnant women may cause hirsutism and virilization in the woman and virilization of female fetuses. The major causes of gestational hyperandrogenism and some of their clinical characteristics are shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef59214 \" href=\"UTD.htm?8/50/9003\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66532 \" href=\"UTD.htm?35/31/36347\">",
"     table 2",
"    </a>",
"    ). These disorders are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=see_link\">",
"     \"Causes of gestational hyperandrogenism\"",
"    </a>",
"    .) This topic will review the clinical manifestations, diagnosis, and treatment of hyperandrogenism in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of androgen excess usually arises when a pregnant woman presents with the rapid onset of masculinization. Affected women may have a variety of symptoms including hirsutism (at times requiring shaving), acne, temporal balding, clitoromegaly, and deepening of the voice.",
"   </p>",
"   <p>",
"    There may also be a palpable abdominal mass due to a tumor or cyst. Causes of the masses include luteomas, theca-lutein cysts, other ovarian tumors, and adrenal tumors. No masses would be expected when the etiology is exposure to exogenous hormones or placental aromatase deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=see_link\">",
"     \"Causes of gestational hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At other times, gestational hyperandrogenism is first suspected at the time of delivery of a virilized female infant. If the investigation begins after delivery, one must keep in mind that luteomas and theca-lutein cysts undergo spontaneous regression after delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating a woman with gestational hyperandrogenism, the possibility that a masculinizing lesion may be malignant is sufficient to warrant a thorough evaluation (",
"    <a class=\"graphic graphic_algorithm graphicRef60418 \" href=\"UTD.htm?39/47/40703\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31236/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Examples of malignant tumors associated with gestational hyperandrogenism include Sertoli-Leydig cell tumors, granulosa-theca cell tumors, Krukenberg tumors, ovarian mucinous cystadenocarcinomas, and adrenocortical carcinomas. Although very rare in pregnancy, Cushing's syndrome should also be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time of onset of hirsutism and virilization should be determined, and information about postmenopausal hormone therapy should be obtained. The probable extent of fetal virilization and the likely causes of the hyperandrogenism may be estimated by the time of onset of maternal symptoms. Exposure to androgens in early pregnancy is likely to cause labioscrotal fusion and clitoromegaly (which may be irreversible and require surgical correction if the child is to be raised as a female); in contrast, exposure after 12 weeks gestation causes only clitoral hypertrophy.",
"   </p>",
"   <p>",
"    Chronic hirsutism is most likely to be associated with theca-lutein cysts, although gestational recurrence of virilizing tumors has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31236/abstract/3\">",
"     3",
"    </a>",
"    ]. The onset of masculinization during pregnancy suggests other causes. Trophoblastic disease should be given particular consideration in women presenting early in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic ultrasonography should be performed in women with the acute onset of virilization or worsening of preexisting hirsutism or virilization during pregnancy. Ultrasonography is helpful in distinguishing solid and cystic ovarian tumors, unilateral from bilateral ovarian disease, and ovarian from adrenal tumors (",
"    <a class=\"graphic graphic_algorithm graphicRef60418 \" href=\"UTD.htm?39/47/40703\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Theca-lutein cysts are almost always bilateral [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31236/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      About one-half of luteomas, which are solid tumors, are bilateral",
"     </li>",
"     <li>",
"      Krukenberg tumors are solid and usually bilateral",
"     </li>",
"     <li>",
"      Other ovarian tumors are usually unilateral",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a unilateral mass, particularly if solid, increases the likelihood of malignancy.",
"   </p>",
"   <p>",
"    At the present time, the ability of ultrasonography to predict fetal sex is not reliable until after differentiation of the genitalia. As a result, its use for evaluation of fetal virilization is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very little information exists on the use of laparoscopy in the diagnosis of gestational hyperandrogenism, but laparoscopy with ovarian biopsy would be expected to be helpful in women with virilization in the first trimester. There has been a report of laparoscopic decompression of large theca-lutein cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31236/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hormone determinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pregnancy is characterized by a progressive increase in serum total testosterone concentrations, due primarily to an increase in serum sex-hormone binding globulin concentrations, and a late increase in serum free testosterone and androstenedione concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35798?source=see_link\">",
"     \"Androgen production and metabolism in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal serum androgen concentrations (usually testosterone and androstenedione) are high in women with gestational hyperandrogenism of endogenous origin. However, in those women in whom the virilization is caused by exogenous hormone administration, the values may be low because the offending hormone is usually a synthetic steroid not measured in assays for testosterone or other androgens.",
"   </p>",
"   <p>",
"    Fetal virilization is indicative of high maternal serum androgen concentrations. However, not all women with high serum androgen concentrations deliver infants that are virilized. As an example, fetal virilization is rare with theca-lutein cysts (",
"    <a class=\"graphic graphic_table graphicRef66532 \" href=\"UTD.htm?35/31/36347\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=see_link\">",
"     \"Causes of gestational hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Percutaneous umbilical blood sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous umbilical blood sampling for testosterone, androstenedione and karyotyping could potentially provide useful prognostic information in women with suspected luteomas if it could be done early enough in gestation. However, this procedure is not generally performed until 20 weeks' gestation, after the time at which virilization would have occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Harvesting fetal cells from the maternal circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Harvesting fetal cells from the maternal circulation offers promise in determining fetal gender and the potential risk of virilization. The presence of these placental cells was originally described in the lungs of women who died from complications of eclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31236/abstract/8\">",
"     8",
"    </a>",
"    ]. Cell-free fetal DNA can be detected in plasma of pregnant women as early as six weeks of gestation and concentrations rise during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31236/abstract/9\">",
"     9",
"    </a>",
"    ]. Using quantitative PCR, circulating fetal DNA can be used as a source of genetic material for noninvasive prenatal evaluation. This technique has been used to determine fetal gender and has also been used to evaluate for genetic diseases and aneuploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31236/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. While still of somewhat limited clinical use, the finding of a male fetus eliminates concern about potential fetal virilization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to therapy of women with gestational hyperandrogenism is determined in large part by the natural history of the underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Luteomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Luteoma should be suspected in women with bilateral solid ovarian masses, but Krukenberg tumor is possible. The mother can expect regression and disappearance of the luteomas after delivery.",
"   </p>",
"   <p>",
"    Approximately 35 percent of women with luteomas have hirsutism or virilization. Among these women, greater than 80 percent will likely have fetuses that are virilized; in contrast, fetal virilization is rare if the mother has no clinical manifestations of androgen excess. Despite these general relationships, fetuses at risk for virilization can be identified only by umbilical blood sampling which, as noted above, is not currently recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gestational ovarian theca-lutein cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with theca-lutein cysts, the fetus does not appear to be at risk for virilization, even if maternal serum androgen concentrations are high. These cysts regress after delivery and should not require surgical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 7 percent of ovarian tumors occurring during pregnancy are malignant. However, the risk of malignancy approaches 50 percent if the woman is virilized and has a unilateral solid ovarian mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exogenous hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of maternal and fetal virilization from exogenous hormone exposure is unknown. With respect to the fetus, the effects would depend on the time of exposure as described above, with early exposure being associated with the risk of potentially irreversible changes such as labioscrotal fusion. There is no evidence that cord blood measurements of androgens and progestins are helpful in determining the risk of fetal virilization in cases of exogenous hormone exposure. Maternal hirsutism or virilization should regress after cessation of hormone administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Placental aromatase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal masculinization would be expected to regress in the postpartum period in women with placental aromatase deficiency. Irreversible virilization can occur in the infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four general principles that should guide management of women with gestational hyperandrogenism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High umbilical cord serum concentrations of testosterone and androstenedione (based upon four cases) appear to be necessary for virilization of a female infant. Thus, the risk of virilization would be low in a woman with a luteoma and normal cord serum androgen concentrations.",
"     </li>",
"     <li>",
"      Exposure of a female fetus to high androgen concentrations in early pregnancy is associated with a risk of irreversible virilization.",
"     </li>",
"     <li>",
"      It is not thought that male infants are at risk.",
"     </li>",
"     <li>",
"      It may be possible to determine fetal gender as early as the first trimester by obtaining fetal cells from the maternal circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgery is not generally indicated in women with luteomas or theca-lutein cysts because both lesions regress in the postpartum period. If, however, the history and evaluation suggests a tumor, laparoscopy or laparotomy may be indicated to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperandrogenism in pregnant women may cause hirsutism and virilization in the mother and virilization of a female fetus. The major causes of gestational hyperandrogenism and some of their clinical characteristics are shown in the tables (",
"      <a class=\"graphic graphic_table graphicRef59214 \" href=\"UTD.htm?8/50/9003\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66532 \" href=\"UTD.htm?35/31/36347\">",
"       table 2",
"      </a>",
"      ), and are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=see_link\">",
"       \"Causes of gestational hyperandrogenism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation includes biochemical testing of serum androgens and pelvic ultrasound of the ovaries. Percutaneous umbilical blood sampling for androgens and karyotyping, which could potentially provide useful information in women with suspected luteomas, is typically performed after virilization has already occurred (eg, &gt;20 weeks' gestation).",
"     </li>",
"     <li>",
"      Antepartum treatment is usually not possible, despite the ability to recognize the clinical manifestations of gestational hyperandrogenism and the availability of technology to evaluate fetal androgen exposure. Percutaneous umbilical blood sampling is generally not warranted because it cannot be performed prior to the occurrence of fetal virilization. Harvesting fetal cells from the maternal circulation is a new technique that offers promise in determining fetal gender; when a male fetus is identified, virilization concerns are eliminated.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/1\">",
"      McClamrock HD, Adashi EY. Gestational hyperandrogenism. Fertil Steril 1992; 57:257.",
"     </a>",
"    </li>",
"    <li>",
"     McClamrock HD, Adashi EY. Gestational hyperandrogenism. In: Reproductive Endocrinology, Surgery, and Technology, Adashi EY, Rock JA, Rosenwaks Z (Eds), Lippincott-Raven, Philadelphia 1996. p.1612.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/3\">",
"      Chen CH, Chen IC, Wang YC, et al. Boy born after gender preselection following successive gestational androgen excess of maternal luteoma and female disorders of sex development. Fertil Steril 2009; 91:2732.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/4\">",
"      Caspi E, Schreyer P, Bukovsky J. Ovarian lutein cysts in pregnancy. Obstet Gynecol 1973; 42:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/5\">",
"      Magendantz HG, Jones DE, Schomberg DW. Virilization during pregnancy associated with polycystic ovary disease. Obstet Gynecol 1972; 40:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/6\">",
"      Wajda KJ, Lucas JG, Marsh WL Jr. Hyperreactio luteinalis. Benign disorder masquerading as an ovarian neoplasm. Arch Pathol Lab Med 1989; 113:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/7\">",
"      Montz FJ, Schlaerth JB, Morrow CP. The natural history of theca lutein cysts. Obstet Gynecol 1988; 72:247.",
"     </a>",
"    </li>",
"    <li>",
"     Schmori, G. Pathologisch-Antomische Untersuchungen uber Puerperal Eklampsie, Verlag FCW Vogel, Leipzig, Germany, 1893.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/9\">",
"      Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/10\">",
"      Lo YM, Patel P, Wainscoat JS, et al. Prenatal sex determination by DNA amplification from maternal peripheral blood. Lancet 1989; 2:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/11\">",
"      Bianchi DW, Simpson JL, Jackson LG, et al. Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study. Prenat Diagn 2002; 22:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/12\">",
"      Johnson KL, Dukes KA, Vidaver J, et al. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clin Chem 2004; 50:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31236/abstract/13\">",
"      Jorgez CJ, Dang DD, Wapner R, et al. Elevated levels of total (maternal and fetal) beta-globin DNA in maternal blood from first trimester pregnancies with trisomy 21. Hum Reprod 2007; 22:2267.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7449 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31236=[""].join("\n");
var outline_f30_32_31236=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS AND SIGNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hormone determinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Percutaneous umbilical blood sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Harvesting fetal cells from the maternal circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS AND THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Luteomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gestational ovarian theca-lutein cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exogenous hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Placental aromatase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7449\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7449|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/47/40703\" title=\"algorithm 1\">",
"      Dx gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7449|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/50/9003\" title=\"table 1\">",
"      Causes gestational hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/31/36347\" title=\"table 2\">",
"      Feature gestational androgenism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35798?source=related_link\">",
"      Androgen production and metabolism in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18470?source=related_link\">",
"      Causes of gestational hyperandrogenism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31237="Sodium oxybate (gamma hydroxybutyrate): Patient drug information";
var content_f30_32_31237=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium oxybate (gamma hydroxybutyrate): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=see_link\">",
"     see \"Sodium oxybate (gamma hydroxybutyrate): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xyrem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3011947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xyrem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming. Make sure that you learn about this drug, what it is used for, how to use it, and when to go back to your doctor. Avoid beer, wine, mixed drinks, or any drugs that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4090003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may slow down your breathing too much. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get this only from the Xyrem&reg; Patient Success Program&reg;.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691778",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sudden emotional shock with loss of muscle tone (cataplexy) in patients with narcolepsy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium oxybate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703839",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have succinic semialdehyde dehydrogenase deficiency.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt or salt-free diet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink beer, wine, or mixed drinks or take any drugs that have alcohol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness or thoughts of taking your own life, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697800",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions for at least 6 hours after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697886",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bedwetting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sleepwalking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695884",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep the time the same between the last food of the day and the first dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695925",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 2 doses each night.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at the same time every night.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prepare each dose before going to bed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix liquid with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        4",
"       </sub>",
"       cup of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695510",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place in child-resistant dosing cups on bedside table.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take first dose at bedtime after getting into bed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space doses by at least 2",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       to 4 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Set alarm clock to wake up for second dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695676",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stay in bed after taking doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696517",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss the second dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699399",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in the original container at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699657",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any unused drug by flushing down a toilet or sink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11049 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31237=[""].join("\n");
var outline_f30_32_31237=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175564\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011947\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023469\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023471\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023470\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023475\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023476\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023478\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023473\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023474\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023479\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023480\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15990?source=related_link\">",
"      Sodium oxybate (gamma hydroxybutyrate): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31238="AIDS-related Kaposis sarcoma - plaque";
var content_f30_32_31238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AIDS-related Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A violaceous plaque representing Kaposi's sarcoma is shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31238=[""].join("\n");
var outline_f30_32_31238=null;
var title_f30_32_31239="Type 2 diabetes mellitus and diet";
var content_f30_32_31239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31239/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31239/contributors\">",
"     Linda M Delahanty, MS, RD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31239/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31239/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31239/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31239/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31239/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/32/31239/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diet and physical activity are critically important in the management of the ABCs (",
"    <strong>",
"     A",
"    </strong>",
"    1c,",
"    <strong>",
"     B",
"    </strong>",
"    lood pressure and",
"    <strong>",
"     C",
"    </strong>",
"    holesterol) of type 2 diabetes.",
"   </p>",
"   <p>",
"    To effectively manage A1C (hemoglobin A1C) and blood sugar levels, it is important to understand how to balance food intake, physical activity, and medication. Making healthy food choices every day has both immediate and long-term effects. With education, practice, and assistance from a dietitian",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a diabetes educator, it is possible to eat well and control diabetes.",
"   </p>",
"   <p>",
"    This article discusses diet in the management of type 2 diabetes. The role of diet and activity in managing blood pressure and cholesterol are reviewed separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"     \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"     \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Articles that discuss other aspects of type 2 diabetes are also available. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"     \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"     \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"     \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"     \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"     \"Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"     \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHY IS DIET IMPORTANT?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many factors affect how well diabetes is controlled. Many of these factors are controlled by the person with diabetes, including how much and what is eaten, how frequently the blood sugar is monitored, physical activity levels, and accuracy and consistency of medication dosing. Even small changes can affect blood sugar control.",
"   </p>",
"   <p>",
"    Eating a consistent amount of food every day and taking medications as directed can greatly improve blood sugar control and decrease the risk of diabetes-related complications, such as coronary artery disease, kidney disease, and nerve damage. In addition, these measures impact weight control. A dietitian can help to create a food plan that is tailored to a person's medical needs, lifestyle, and personal preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES AND MEAL TIMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistently eating at the same times every day is important for some people, especially those who take long-acting insulin (eg, NPH) and oral medications that decrease blood sugar levels (sulfonylureas or meglitinides). If a meal is skipped or delayed while on these regimens, you are at risk for developing low blood glucose.",
"   </p>",
"   <p>",
"    People who use intensive insulin therapy (those on multiple daily injections) and people who take other types of oral diabetes medications (eg, insulin sensitizers such as",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?0/22/358?source=see_link\">",
"     metformin",
"    </a>",
"    ) have more flexibility around meal timing. With these regimens, skipping or delaying a meal does not usually increase the risk of low blood sugar.",
"   </p>",
"   <p>",
"    Foods or meals that are high in fat (eg, pizza) may be eaten occasionally, although blood sugar levels should be monitored more closely. High-fat meals are broken down more slowly than low-fat meals. When using rapid acting insulin before a meal, the blood sugar level may become low shortly after eating a high fat meal and then rise hours later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many people with type 2 diabetes are overweight. Losing even a small amount of weight (5 to 10 percent of total body weight) can help the body to produce and use insulin more efficiently. In fact, eating fewer calories can reduce blood sugar levels even before the first pound is lost.",
"   </p>",
"   <p>",
"    There are several strategies that can aid in weight loss, including eating fewer calories, exercise, weight loss medications, and weight loss surgery. These treatments are discussed in detail in separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"     \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommended calorie intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of calories needed to maintain weight depends upon your age, sex, height, weight, and activity level. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Men, active women - 15",
"      <span class=\"nowrap\">",
"       cal/lb",
"      </span>",
"     </li>",
"     <li>",
"      Most women, sedentary men, and adults over 55 years - 13",
"      <span class=\"nowrap\">",
"       cal/lb",
"      </span>",
"     </li>",
"     <li>",
"      Sedentary women, obese adults - 10",
"      <span class=\"nowrap\">",
"       cal/lb",
"      </span>",
"     </li>",
"     <li>",
"      Pregnant, lactating women - 15 to 17",
"      <span class=\"nowrap\">",
"       cal/lb",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To lose 1 to 2 pounds per week (a safe rate of weight loss), subtract 500 to 1000 calories from the total number of calories needed to maintain weight.",
"   </p>",
"   <p>",
"    As an example, an overweight man who weighs 250 lbs would need to eat 2500 calories per day to maintain his weight. To lose 1 to 2 pounds per week, he should eat 1500 to 2000 calories per day. As weight is lost, the recommended calorie intake should be recalculated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES, DIET, AND WEIGHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your weight is a direct reflection of how much you eat and how active you are. Eating a consistent number of calories every day can help to control blood glucose levels and maintain body weight. In people who are overweight or obese, losing weight by eating fewer calories or increasing activity levels can improve blood sugar control, and lower blood pressure and cholesterol levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Avoiding weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain is a potential side effect of intensive insulin therapy in type 2 diabetes. Weight gain is also a side effect of some oral medications used for people with type 2 diabetes. To avoid weight gain, the following tips are recommended.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measure your weight on a regular basis (eg, once weekly). Weight gains of more than 2 to 3 pounds indicate a need to decrease the amount you eat or increase activity. Do not wait until weight increases by 10 or more pounds to take action.",
"     </li>",
"     <li>",
"      As blood glucose control improves, it may be necessary to decrease your calorie intake by 250 to 300 calories per day to avoid weight gain.",
"     </li>",
"     <li>",
"      If blood glucose levels are frequently low at a particular time of day, decrease the insulin dose or medication dose rather than add a snack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercising regularly can help to lose weight and keep it off. The recommended amount of exercise is 30 minutes per day most days of the week. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"     \"Patient information: Exercise (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    People who take insulin or oral medications that lower blood sugar levels should check their blood glucose level before and after exercising. If exercise is vigorous and prolonged (more than 30 minutes), check the blood glucose every 15 minutes (if the exercise regimen is new and will be used again). Frequent monitoring can help to get a sense of what effect exercise has on the blood glucose level.",
"   </p>",
"   <p>",
"    If your blood sugar level becomes low during exercise, eat a snack according to the guidelines below. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"     \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the blood glucose is 51 to 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8 to 3.8",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      eat 10 to 15 grams of fast-acting carbohydrate (eg,",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      cup fruit juice, 6 to 8 hard candies, 3 to 4 glucose tablets).",
"     </li>",
"     <li>",
"      If the level is less than 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.7",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      eat 20 to 30 grams of fast-acting carbohydrates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retest after 15 minutes and repeat treatment if blood glucose is still too low. If your next meal is more than an hour away, eat an additional 15 grams of carbohydrate and 1 ounce of protein (for example, crackers with cheese or one-half of a sandwich with peanut butter). It is important not to eat too much because this can raise blood sugar levels above the target level and lead to weight gain over the long term.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adjusting insulin dose for exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;People who take oral diabetes medications usually do not need to adjust the dose of these medications for exercise.",
"   </p>",
"   <p>",
"    If you take insulin, it may be possible to reduce your insulin dose before exercising to avoid developing low blood glucose. A physician, diabetes educator, dietitian or exercise physiologist can help to determine the best way to adjust your insulin dose before, during, and after exercising.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES AND ALCOHOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drinking a moderate amount of alcohol (up to 1 serving per day for women, up to 2 servings per day for men) with food does not affect blood glucose levels significantly. Alcohol may cause a slight rise in blood glucose, followed hours later by a decrease in the blood glucose level. As a result, it is important to monitor blood glucose response to alcohol to determine if any changes in insulin doses are needed.",
"   </p>",
"   <p>",
"    Mixers, such as fruit juice or regular cola, can increase blood glucose levels and increase the number of calories consumed in a day. Also, calories from alcohol have little nutritional value and may interfere with efforts to lose weight or contribute to weight gain. If you take oral diabetes medications, you will not need to adjust your medication, as long as you drink the alcohol in moderation and with food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TYPE 2 DIABETES AND CARBOHYDRATE CONSISTENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbohydrates are the main energy source in the diet, and include starches, vegetables, fruits, dairy products, and sugars. Most meats and fats do not contain any carbohydrates.",
"   </p>",
"   <p>",
"    Carbohydrates have a direct impact on the blood glucose level whereas proteins and fat have little to no impact. Eating a consistent amount of carbohydrates at each meal can help to control blood glucose levels, especially in people who take oral diabetes medications or long-acting insulin (eg, NPH).",
"   </p>",
"   <p>",
"    People with type 2 diabetes should focus on reducing calories and increasing physical activity, especially when newly diagnosed or if the pancreas is still producing some insulin. People who have type 2 diabetes and are lean or not interested in losing weight loss could consider a focus on maintaining their weight with carbohydrate counting. Carbohydrate counting may also be helpful for those who are on multiple daily injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Carbohydrate counting",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dietitian usually helps to determine the number of carbohydrates you need at each meal and snack, based upon an individual's usual eating habits, diabetes medications, body weight, nutritional goals, and activity level. In most people, between 45 and 65 percent of the day's total calories should come from carbohydrates. The way carbohydrates are divided up for each meal or snack is based upon personal preferences, meal timing and spacing, and type of diabetes medications (",
"    <a class=\"graphic graphic_table graphicRef73017 \" href=\"UTD.htm?36/1/36891\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The number of carbohydrates in a food can be determined by reading the nutrition label, consulting a reference book or website, carrying a database on a personal digital assistant (PDA), or using the Exchange system. Restaurants usually have this information available upon request. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Where to get more information'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is important to note the serving size and grams of fiber when calculating carbohydrates. Eating more than one serving will increase the number of calories consumed and the dose of insulin needed to cover the meal. For example, some pre-packaged snacks contain two or more servings. To calculate the carbohydrate content of the entire package, multiply the number of servings by the number of carbohydrates per serving.",
"   </p>",
"   <p>",
"    When a serving of food has more than 5 grams of fiber, the grams of fiber should be subtracted from the grams of carbohydrates to calculate the insulin dose (",
"    <a class=\"graphic graphic_figure graphicRef76576 \" href=\"UTD.htm?0/2/40\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28778175\">",
"    <span class=\"h2\">",
"     Exchange planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;With exchange planning, all foods are categorized as either a carbohydrate, meat or meat substitute, or fat. In this system, one serving of a carbohydrate (eg, one small apple) can be exchanged for any other carbohydrate (eg,",
"    <span class=\"nowrap\">",
"     1/3",
"    </span>",
"    cup cooked pasta), because both portions contain about 15 grams of carbohydrate. You can also easily determine the carbohydrate content of your meals and snacks using the Exchange system (",
"    <a class=\"graphic graphic_table graphicRef70878 \" href=\"UTD.htm?22/35/23101\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The exchange lists also identify foods that are good sources of fiber, and foods that have a high sodium content. A dietitian can help you determine how many servings of each group should be eaten at each meal and snack (",
"    <a class=\"graphic graphic_table graphicRef70878 \" href=\"UTD.htm?22/35/23101\">",
"     table 2",
"    </a>",
"    ) and the typical carbohydrate content of each meal and snack.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intensive insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;People who take multiple injections of rapid-acting insulin per day can adjust their pre-meal insulin dose based upon the number of carbohydrates they plan to eat and their pre-meal blood glucose. This requires the person to perform basic arithmetic.",
"   </p>",
"   <p>",
"    The pre-meal insulin dose is calculated by dividing the number of carbohydrates to be consumed by the number of carbohydrates covered by one unit of insulin (insulin-to-carbohydrate ratio). This dose is then adjusted based upon the pre-meal blood glucose reading (see below).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin-to-carbohydrate ratio &mdash; An insulin-to-carbohydrate ratio is determined by a dietitian or diabetes educator. This allows the person to calculate the dose of rapid-acting insulin needed to cover a meal or snack.",
"      <br/>",
"      <br/>",
"      For example, if the insulin-to-carbohydrate ratio is 1 to 10, the person would give 1 unit of insulin for every 10 grams of carbohydrate consumed. If the person ate a meal with 70 grams of carbohydrates, the dose of rapid-acting insulin would be 7 units.",
"     </li>",
"     <li>",
"      Correction factor &mdash; The pre-meal insulin dose can also be adjusted based upon the pre-meal blood glucose level; this is called a correction factor. The correction factor can be determined by a dietitian or diabetes educator.",
"      <br/>",
"      <br/>",
"      For example, let's assume that the correction factor is 30. If the pre-meal blood glucose was 240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and the goal BG was 120",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      take 240 minus 120 = 120. Then 120 divided by 30 = 4 extra units of insulin to correct the high blood glucose level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     WHAT SHOULD I EAT?",
"    </span>",
"    &nbsp;&mdash;&nbsp;While protein and fat do not affect blood glucose levels significantly, they do contribute to the number of calories consumed. Eating a consistent number of calories every day can help to maintain body weight. An individual's recommended calorie intake is discussed below. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Recommended calorie intake'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Diabetes Association recommends the following to help manage the ABCs (",
"    <strong>",
"     A",
"    </strong>",
"    1c,",
"    <strong>",
"     B",
"    </strong>",
"    lood pressure and",
"    <strong>",
"     C",
"    </strong>",
"    holesterol) and promote good health:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 25 and 35 percent of calories per day should be from fat, and less than 7 percent of calories per day should be from saturated fat; there should be minimal trans fat. Saturated and trans fats are found in solid fats like cheese, red meats, butter, margarine, and shortening. People with diabetes are at increased risk for heart disease and stroke, and eating a diet low in saturated and trans fats and cholesterol can help to reduce cholesterol levels and decrease these risks.",
"     </li>",
"     <li>",
"      Total cholesterol intake should be less than 200 mg per day. The main sources of cholesterol in the diet are foods such as organ meats and egg yolks. Shrimp and squid are also moderately high in cholesterol but can be included in your diet occasionally because they are low in fat.",
"     </li>",
"     <li>",
"      Between 15 and 20 percent of calories should be from protein, except in people with certain kidney problems (chronic kidney disease or CKD). People with CKD are sometimes advised to eat a low-protein diet. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A diet that is high in fiber (25 to 30 grams per day) may help to control blood glucose levels and hemoglobin A1c. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"       \"Patient information: High-fiber diet (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A diet that is low in sodium (less than 1500 mg per day) and that is high in fruits, vegetables, and low fat dairy products, is recommended and can help manage blood pressure. For people with diabetes and heart failure, a low sodium diet may reduce symptoms. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"       \"Patient information: Low sodium diet (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Artificial sweeteners do not affect blood glucose levels and may be consumed in moderation. The US Food and Drug Administration (FDA) has tested and approved five artificial sweeteners: aspartame (Equal, NutraSweet), saccharin (Sweet'N Low, Sweet Twin), acesulfame-K (Sunnet, Sweet One), neotame, and sucralose (Splenda). Stevia (sometimes called Rebaudioside A or rebiana) comes from the stevia plant and is now generally recognized as safe by the FDA as a food additive and table top sweetener. When something is generally recognized as safe by the FDA, it means that experts have agreed that it is safe for use by the public in appropriate amounts.",
"      <br/>",
"      <br/>",
"      Sugar alcohols (",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?12/16/12548?source=see_link\">",
"       sorbitol",
"      </a>",
"      , xylitol, lactitol,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?28/34/29221?source=see_link\">",
"       mannitol",
"      </a>",
"      , and maltitol) are often used to sweeten sugar-free candies and gum, and increase blood glucose levels slightly. When calculating the carbohydrate content of foods, one-half of the sugar alcohol content should be counted in the total carbohydrate content of the food. Eating too much sugar alcohol at one time can cause cramping, gas, and diarrhea.",
"     </li>",
"     <li>",
"      Previously, people with diabetes were told to avoid all foods with added sugar. This is no longer recommended, although sugar should be eaten in moderation. If you take insulin, you should calculate your dose based upon the total number of carbohydrates in the food, which includes the sugar content, as described above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Carbohydrate counting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Products that are \"sugar-free\" or \"fat-free\" do not necessarily have a reduced number of calories or carbohydrates. Read the nutrition label carefully and compare it to other similar products that are not sugar- or fat-free to determine which has the best balance of serving size and number of calories, carbohydrates, fat, and fiber.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some sugar-free foods, such as diet soda, sugar-free gelatin, and sugar-free gum, do not have a significant number of calories or carbohydrates, and are considered \"free foods.\" Any food that has less than 20 calories and 5 grams of carbohydrate is considered a free food, meaning that they do not affect body weight or require additional medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2287426346\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181963487\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"     Patient information: Type 2 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"     Patient information: Diabetes and diet (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"     Patient information: Diet and health (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"     Patient information: High-fiber diet (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?34/42/35490?source=see_link\">",
"     Patient information: Counting carbs if you do not use insulin (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=see_link\">",
"     Patient information: Treatment for type 2 diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=see_link\">",
"     Patient information: The ABCs of diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?14/47/15091?source=see_link\">",
"     Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=see_link\">",
"     Patient information: Preventing type 2 diabetes (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H181963727\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"     Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"     Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"     Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"     Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"     Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"     Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"     Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"     Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"     Patient information: Weight loss treatments (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"     Patient information: Exercise (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"     Patient information: Chronic kidney disease (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"     Patient information: High-fiber diet (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"     Patient information: Low sodium diet (Beyond the Basics)",
"    </a>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link\">",
"     Dietary carbohydrates",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"     Effects of exercise in diabetes mellitus in adults",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link\">",
"     Estimation of blood glucose control in diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     Glycemic control and vascular complications in type 2 diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     Initial management of blood glucose in type 2 diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     Insulin therapy in type 2 diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     Management of persistent hyperglycemia in type 2 diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     Metformin in the treatment of diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"     Nutritional considerations in type 2 diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"     Overview of medical care in adults with diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link\">",
"     Thiazolidinediones in the treatment of diabetes mellitus",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"     www.nlm.nih.gov/medlineplus/healthtopics.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"     www.niddk.nih.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Diabetes Association (ADA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.diabetes.org/\">",
"     www.diabetes.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Endocrine Society",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.endo-society.org/\">",
"     www.endo-society.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Hormone Foundation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"     www.hormone.org/public/diabetes.cfm",
"    </a>",
"    , available in English and Spanish)",
"   </p>",
"   <p>",
"    The following reference books are a good source of information regarding diabetes and diet and carbohydrate counting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Doctor's Pocket Calorie, Fat, and Carb Counter, Allan Borushek, also available for download to personal digital assistant at",
"      <a class=\"external\" href=\"file://www.calorieking.com/\">",
"       www.calorieking.com",
"      </a>",
"     </li>",
"     <li>",
"      Practical Carbohydrate Counting, Hope Warshaw and Karmeen Kulkarni",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31239/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31239/abstract/1\">",
"      Pastors JG, Warshaw H, Daly A, et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002; 25:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31239/abstract/2\">",
"      American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004; 27 Suppl 1:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31239/abstract/3\">",
"      Polonsky WH, Anderson BJ, Lohrer PA, et al. Insulin omission in women with IDDM. Diabetes Care 1994; 17:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31239/abstract/4\">",
"      American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 Suppl 1:S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31239/abstract/5\">",
"      Sheard NF, Clark NG, Brand-Miller JC, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. Diabetes Care 2004; 27:2266.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1748 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31239=[""].join("\n");
var outline_f30_32_31239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      TYPE 2 DIABETES OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHY IS DIET IMPORTANT?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TYPE 2 DIABETES AND MEAL TIMING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommended calorie intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TYPE 2 DIABETES, DIET, AND WEIGHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Avoiding weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adjusting insulin dose for exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TYPE 2 DIABETES AND ALCOHOL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TYPE 2 DIABETES AND CARBOHYDRATE CONSISTENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Carbohydrate counting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28778175\">",
"      Exchange planning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intensive insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      WHAT SHOULD I EAT?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      General recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2287426346\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181963487\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H181963727\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/1748\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/1748|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/2/40\" title=\"figure 1\">",
"      Nutrition label PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/1748|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/1/36891\" title=\"table 1\">",
"      Carb counting PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/35/23101\" title=\"table 2\">",
"      Exchange system menu PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=related_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/42/35490?source=related_link\">",
"      Patient information: Counting carbs if you do not use insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=related_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/47/15091?source=related_link\">",
"      Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=related_link\">",
"      Patient information: Preventing type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=related_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/49/16147?source=related_link\">",
"      Patient information: Treatment for type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31240="Hemodynamic instability during hemodialysis: Overview";
var content_f30_32_31240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hemodynamic instability during hemodialysis: Overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31240/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31240/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31240/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31240/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31240/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31240/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/32/31240/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual manifestation of hemodynamic instability during ultrafiltration dialysis (in which fluid removal is the primary goal) is hypotension. The incidence of a symptomatic reduction in blood pressure during (or immediately following) dialysis ranges from 15 to 50 percent of dialysis sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/1\">",
"     1",
"    </a>",
"    ]. In some patients, the development of orthostatic hypotension necessitates intravenous fluid replacement before they are able to leave the dialysis unit. This problem contributes to the excessive morbidity that is associated with the dialysis procedure.",
"   </p>",
"   <p>",
"    There are two clinical patterns of dialysis-associated hypotension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Episodic hypotension, which typically occurs during the latter stages of dialysis; this is associated with vomiting, muscle cramps, and other vagal symptoms (such as yawning).",
"     </li>",
"     <li>",
"      Chronic persistent hypotension, which may occur in long-term patients in whom predialysis systolic blood pressures of less than 100 mmHg are frequently observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although hypotension during hemodialysis is a frequent complication, some patients develop paradoxical hypertension in the later stages of dialysis. This problem is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link&amp;anchor=H22#H22\">",
"     \"Hypertension in dialysis patients\", section on 'Hypertension during hemodialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many factors may contribute to dialysis hypotension, many of which are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A rapid reduction in plasma osmolality, which causes extracellular water to move into the cells (",
"      <a class=\"graphic graphic_figure graphicRef53752 \" href=\"UTD.htm?3/31/3582\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"       \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid fluid removal in an attempt to attain \"dry weight\", particularly among those with large interdialytic weight gains [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inaccurate determination of true \"dry weight\" [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"       \"Hypertension in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autonomic neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=see_link\">",
"       \"Autonomic dysfunction in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diminished cardiac reserve. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Improvement in cardiovascular performance'",
"      </a>",
"      below.) [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of acetate rather than bicarbonate as a dialysate buffer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=see_link\">",
"       \"Overview of the hemodialysis apparatus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intake of antihypertensive medications that can impair cardiovascular stability. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"       \"Hypertension in dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of a lower sodium concentration in the dialysate (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"       \"Hypertension in dialysis patients\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Sudden release of adenosine during organ ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ingestion of a meal immediately before or during dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arrhythmias or pericardial effusion with tamponade, which are volume-unresponsive causes of hypotension.",
"     </li>",
"     <li>",
"      Reactions to the dialyzer membrane, which may cause wheezing and dyspnea as well as hypotension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"       \"Reactions to the hemodialysis membrane\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased synthesis of endogenous vasodilators, such as nitric oxide [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High magnesium concentrations in the dialysate [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Failure to increase plasma",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"       vasopressin",
"      </a>",
"      levels [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative magnitude of the contribution of each of these factors is not known. In one prospective study of 218 hemodialysis patients, intradialytic systolic blood pressure variability described by the deviation of systolic blood pressure from its anticipated course, or by the absolute difference between successive measurements, was associated with older age, shorter dialysis vintage and greater volume removal [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/4\">",
"     4",
"    </a>",
"    ]. Blood pressure variability was not associated with patient characteristics including race, gender or comorbidities, or dialysis-related factors including session length, blood flow rate, timing of the dialysis session, potassium concentration or sodium modeling [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/4\">",
"     4",
"    </a>",
"    ]. The generalizability of this observational study to may be limited by an overrepresentation of black patients and patients with congestive heart failure, and by a lower interdialytic weight gain than is generally observed.",
"   </p>",
"   <p>",
"    Infrequently, patients with dialysis-induced hypotension have a serious medical condition requiring immediate attention. These include arrhythmias, pericardial tamponade, valvular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/15\">",
"     15",
"    </a>",
"    ], myocardial infarction, hemolysis, hemorrhage, septicemia, and air embolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441018086\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whatever the underlying cause, patients with hemodialysis-associated hypotension have increased mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with frequent intradialytic hypotension are at increased risk of fistula thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/17\">",
"     17",
"    </a>",
"    ]. This was shown in a secondary analysis of the HEMO study in which 1426 subjects were stratified by the percentage of dialysis treatments that were complicated by hypotensive episodes requiring saline infusion, or reduction of either the ultrafiltration rate or blood flow. At three years of follow-up there were 2005 episodes of vascular thrombosis. As has been shown before, the overall rate of thrombosis was much higher among patients with grafts compared with fistulas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=see_link&amp;anchor=H13#H13\">",
"     \"Arteriovenous fistulas and grafts for chronic hemodialysis access\", section on 'Complications'",
"    </a>",
"    .) However, among patients with fistulas, the risk of thrombosis was doubled among those who had more than 30 percent of dialysis treatments complicated by hypotension compared with those who had stable treatments (relative risk of 2.02, 95% CI 1.22 to 3.35). This association was not observed for patients who had prosthetic arteriovenous grafts.",
"   </p>",
"   <p>",
"    This study also demonstrated a correlation of both fistula and graft thrombosis with lower pre- and post-dialysis blood pressures. These data, and the primary results of the HEMO trial, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypertension in dialysis patients\", section on 'Optimal blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link&amp;anchor=H11#H11\">",
"     \"Kt/V and the adequacy of hemodialysis\", section on 'HEMO study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although occasionally asymptomatic, patients with hypotension may suffer from light-headedness, muscle cramps, nausea, vomiting, and dyspnea. The acute management of low blood pressure associated with hemodialysis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ultrafiltration should either be stopped or the rate decreased.",
"     </li>",
"     <li>",
"      The patient should be placed in the Trendelenburg position.",
"     </li>",
"     <li>",
"      The blood flow rate should be reduced.",
"     </li>",
"     <li>",
"      Intravascular volume may be replaced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      or saline. We currently use an intravenous bolus of saline as first-line therapy for hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further treatment is based upon the etiology of the hypotension; the prompt recognition of life-threatening causes of low blood pressure is essential. Particular concerns should include occult sepsis, previously unrecognized cardiac",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pericardial disease, and gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with chronic, debilitating hemodialysis hypotension due to the inability to adequately respond to rapid changes in blood volume may be more likely to tolerate the gradual volume changes associated with peritoneal dialysis or nocturnal hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Increasing the time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequency of hemodialysis is another possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate success can be achieved with therapies aimed at reducing the incidence of symptomatic dialysis hypotension. Among those with proven efficacy, the following appear to be the most beneficial in the patient undergoing maintenance hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Accurate setting of the \"dry weight\"",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, the determination of dry weight is largely determined empirically by trial and error. The dry weight is set at the weight below which unacceptable symptoms, such as cramping, nausea, and vomiting, or hypotension occur. The dry weight is highly variable in many patients, and can fluctuate with intercurrent illnesses (such as diarrhea or infection) and with changes in hemoglobin (as with erythropoietin).",
"   </p>",
"   <p>",
"    A large number of other modalities have been evaluated in an effort to more objectively estimate dry weight [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/5,24-27\">",
"     5,24-27",
"    </a>",
"    ]. These include blood volume monitoring, ultrasound assessment of the inferior vena cava, natriuretic peptide measurements, extravascular lung water indices, and bioimpedance methods [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/27\">",
"     27",
"    </a>",
"    ]. The best comparative studies have generally favored methods that rely upon bioimpedance measurements. These provide an assessment of extracellular and intracellular volume and total body water [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Particular promise lies in a technique in which continuous intradialytic measurements are confined to the calf since the relative volume of excess extracellular fluids is greater in the lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/30\">",
"     30",
"    </a>",
"    ]. In general, further study is required to understand the role, if any, for these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Steady, constant ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some dialysis machines are equipped with accurate ultrafiltration devices that remove volume steadily and evenly over the course of the dialysis session. This has enabled patients to tolerate the procedure with fewer adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/24,31\">",
"     24,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some physicians have advocated the use of modeling protocols in which more (or less) weight is removed at the beginning or end of dialysis. The efficacy of",
"    <span class=\"nowrap\">",
"     ultrafiltration/sodium",
"    </span>",
"    modeling has not been proven, but it may help in selected cases. Increased weight loss has traditionally occurred in the setting of a higher dialysate sodium concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased dialysate sodium concentration and sodium modeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a higher dialysate sodium concentration (&ge;140",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    has been among the most efficacious and best tolerated therapies for episodic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. The high sodium concentration prevents a marked decline in plasma osmolality during dialysis, thereby protecting the extracellular volume by minimizing osmotic fluid loss into the cells.",
"   </p>",
"   <p>",
"    The efficacy of a higher dialysate sodium concentration in preventing hypotension and other untoward dialysis-related side effects was assessed in a blinded, crossover study of 23 patients undergoing 414 dialysis sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/34\">",
"     34",
"    </a>",
"    ]. All patients underwent dialysis for two week periods using the following three sodium dialysate concentration strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A constant sodium concentration of 140",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Linear sodium ramping (155 to 140",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Stepwise sodium ramping (155",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for three hours and 140",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      for one hour)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both sodium ramping protocols resulted in a significant but small decrease in the number of hypotensive episodes compared with constant sodium concentration dialysis (1.3 versus 0.7 symptomatic hypotensive episodes per two weeks).",
"   </p>",
"   <p>",
"    As stated in the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, limitations of dialysate sodium modeling include the lack of correlation between blood volume degree and onset of hypotension, significant individual and interdialysis variations in sodium levels, and thirst and weight gain with postdialysis hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Combination sodium modeling and ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration profiling is characterized by the ultrafiltration rate being intermittently stopped or decreased gradually, thereby resulting in plasma refilling. The combination of ultrafiltration and sodium profiling can further enhance plasma refilling; in turn, this can result in greater stability during hemodialysis.",
"   </p>",
"   <p>",
"    A small well-designed study evaluated different combinations of sodium profiles with or without ultrafiltration in terms of effects on hemodynamic stability, sodium balance, and ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/36\">",
"     36",
"    </a>",
"    ]. They reported that the combination of sodium balance-neutral sodium profiling (step down with a time averaged mean sodium concentration of 138",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and ultrafiltration profiling (stepwise decreasing rate) was associated with less sodium and weight gains, better ultrafiltration, and decreased interdialytic hypotension episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sequential ultrafiltration and isovolemic dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A similar goal of maintenance of the plasma osmolality can be attained by initial ultrafiltration alone (without dialysis) followed by isovolemic dialysis in which little or no further fluid removal occurs due to reduced transmembrane pressures. This sequential procedure often allows a large volume of fluid to be removed without inducing hemodynamic instability (",
"    <a class=\"graphic graphic_figure graphicRef76802 \" href=\"UTD.htm?3/4/3150\">",
"     figure 2",
"    </a>",
"    ). This maneuver, however, is difficult to perform in outpatients since it requires prolongation of the time of dialysis. A discussion of the mechanism of the hemodynamic benefit with isolated ultrafiltration can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bicarbonate dialysate buffer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bicarbonate is now widely available and adaptable to all new dialysis machines. The difference in cost between acetate and bicarbonate dialysis is minimal, while the blood pressure is generally better maintained with bicarbonate. Acetate accumulation in the blood has vasodilator activity that can promote the development of hypotension, and negative effects upon energy metabolism in the heart that can impair cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Temperature control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of low dialysate temperature can improve hemodynamic stability by improving cardiovascular contractility and increasing venous tone [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24690?source=see_link\">",
"     \"Cool temperature hemodialysis: Hemodynamic effects\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Improvement in cardiovascular performance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    During standard hemodialysis, an increase in core temperature is commonly observed, with the underlying causes being ultrafiltration and several other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/39\">",
"     39",
"    </a>",
"    ]. Isothermic dialysis, in which body temperature remains constant during the hemodialysis procedure, may prove useful in stabilizing blood pressure among hypotension-prone patients [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Further study is required to better assess the role of this specific technique.",
"   </p>",
"   <p>",
"    The observation that chronic hemodiafiltration may have improved hemodynamic stability compared with hemodialysis may result directly from different energy transfer profiles. Support for this was provided by a crossover study in which hemodialysis and predilution hemodialysis had equivalent hemodialysis profiles when patient core temperature and other parameters were equivalent with both techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Improvement in cardiovascular performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of dialysis-associated hemodynamic instability is greatly increased in patients with a prior history of heart failure, cardiomegaly, or ischemic heart disease. These conditions lead to poor left ventricular performance, and, importantly, a diminished cardiac reserve in the context of a hemodynamic challenge. Support for the importance of diminished cardiac reserve is provided by the results of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography among 18 patients with dialysis instability and 18 without such instability [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/44\">",
"     44",
"    </a>",
"    ]. The baseline cardiac index was similar in the two groups. However, cardiac reserve, as determined by the increase in cardiac index with dobutamine, was significantly lower among the patients who were prone to hypotension during dialysis (0.8 versus 2.3",
"    <span class=\"nowrap\">",
"     liter/min",
"    </span>",
"    per m2, p = 0.002). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiovascular performance can be enhanced in many dialysis patients in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing the dialysate calcium concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/45\">",
"       45",
"      </a>",
"      ]. However, increased dialysate calcium levels may result in hypercalcemia and decreased bone turnover. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"       \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Using cool temperature hemodialysis, which can also increase vascular resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/46\">",
"       46",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24690?source=see_link\">",
"       \"Cool temperature hemodialysis: Hemodynamic effects\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Correction of anemia with erythropoietin",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Midodrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with autonomic neuropathy and perhaps others with severe hemodialysis hypotension not responsive to the above measures, the selective alpha-1 adrenergic agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    may be effective and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. A 2004 systematic review of 10 studies found that the use of midodrine, compared with controls, was associated with significant increases in the post dialysis blood pressure",
"    <span class=\"nowrap\">",
"     (12.4/7.3",
"    </span>",
"    mmHg) and the nadir blood pressure was also significantly higher with midodrine",
"    <span class=\"nowrap\">",
"     (13.3/5.9",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/50\">",
"     50",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=see_link&amp;anchor=H5#H5\">",
"     \"Autonomic dysfunction in dialysis patients\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Carnitine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    supplementation has reduced the incidence of hypotensive episodes and muscle cramps. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=see_link\">",
"     \"Carnitine metabolism in renal disease and dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Avoidance of food",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food ingestion during dialysis leads to a significant decline in systemic vascular resistance that can contribute to a fall in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/10\">",
"     10",
"    </a>",
"    ]. This effect is not corrected by the concurrent intake of caffeine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adenosine release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine is an endogenous vasodilator that has been related to hypotensive episodes in a subset of patients on hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/9\">",
"     9",
"    </a>",
"    ]. This response can be blunted in some patients by the administration of caffeine, which may act as an adenosine receptor antagonist in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/9\">",
"     9",
"    </a>",
"    ]. The administration of an adenosine receptor antagonist, FK352, was also found to significantly lower episodes of intradialytic hypotension in a small placebo controlled study [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Vasopressin infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been observed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/24/5511?source=see_link\">",
"     vasopressin",
"    </a>",
"    release is not increased in hemodialysis patients undergoing volume removal. To examine whether vasopressin administration may facilitate volume removal, 22 hemodialysis patients were randomly assigned to placebo or constant infusion of a non-pressor dose of vasopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/14\">",
"     14",
"    </a>",
"    ]. Vasopressin was significantly associated with a decreased incidence of symptomatic hypotensive episodes and increased fluid removal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Comparative efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the measures delineated above provide some degree of prophylactic benefit. However, their relative efficacy in the same patient is unclear. This was addressed in a single-blinded crossover study of 10 patients with a history of intradialytic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/52\">",
"     52",
"    </a>",
"    ]. After one week of standard dialysis, all patients underwent one week of each of the following four strategies: high sodium dialysate, sodium modeling, sequential ultrafiltration and isovolemic dialysis, and cool temperature dialysis. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High sodium dialysate, sodium modeling, and cool temperature dialysis resulted in significantly fewer hypotensive events than that observed with standard dialysis.",
"     </li>",
"     <li>",
"      Compared with the other test strategies, sequential ultrafiltration and isovolemic dialysis had a significantly greater number of hypotensive episodes.",
"     </li>",
"     <li>",
"      Post-dialysis upright blood pressure was best with sodium modeling and cool temperature dialysis, compared to that measured with standard and isolated ultrafiltration dialysis.",
"     </li>",
"     <li>",
"      Weight loss was virtually identical with all protocols.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the best tolerated and most effective strategy was sodium modeling. High sodium and cool temperature dialysis were also effective, while sequential ultrafiltration and isovolemic dialysis was significantly less useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with resistant cases of intradialytic hypotension, the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines suggest the use of the following combinations of modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       Midodrine",
"      </a>",
"      and dialysate temperature profiling",
"     </li>",
"     <li>",
"      Dialysate temperature profiling plus 3",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      dialysate calcium level",
"     </li>",
"     <li>",
"      Dialysate temperature and sodium modeling",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated ultrafiltration and other approaches may also provide benefit.",
"   </p>",
"   <p>",
"    The 2007 European best practice guidelines in hemodialysis recommend the following stepped approach to the prevention of intradialytic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First-line approach &mdash; The first-line approach includes dietary counseling (sodium restriction), no food intake during dialysis, clinical dry weight reassessment, bicarbonate as the dialysis buffer, dialysate temperature of 36.5&ordm;C,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      appropriate dosing and timing of antihypertensive agents.",
"     </li>",
"     <li>",
"      Second-line approach &mdash; The second-line approach includes objective methods to assess dry weight, cardiac evaluation, gradual reduction of dialysate temperature from 36.5&ordm;C (lowest 35&ordm;C) or isothermic treatment (possible alternative is convective treatments), consideration of blood volume controlled feedback, increase in dialysis time",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      frequency,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      use of a dialysate calcium concentration of 1.50",
"      <span class=\"nowrap\">",
"       mmol/L.",
"      </span>",
"     </li>",
"     <li>",
"      Third-line approach &mdash; If other treatment options have failed, the guidelines recommend the third-line approach which involves consideration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       L-carnitine",
"      </a>",
"      supplementation or peritoneal dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Recommendations for prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following for the prevention of hemodynamic instability [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31240/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exclude causes that are non-dialysis related, such as myocardial ischemia and pericardial effusion.",
"     </li>",
"     <li>",
"      Efforts should be made to minimize intradialytic weight gain.",
"     </li>",
"     <li>",
"      Dialysis prescription should be altered based upon individual patient characteristics:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Accurate setting of the dry weight",
"     </li>",
"     <li>",
"      Fixed sodium concentration greater than 140",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or sodium modeling",
"     </li>",
"     <li>",
"      Consider cooler temperature dialysis",
"     </li>",
"     <li>",
"      Bicarbonate buffer",
"     </li>",
"     <li>",
"      Avoid low magnesium and low calcium dialysate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrafiltration method should be optimized. This include ultrafiltration modeling alone or with sodium modeling, or sequential ultrafiltration and isovolemic dialysis",
"     </li>",
"     <li>",
"      Avoidance of food and antihypertensive medicines on dialysis day",
"     </li>",
"     <li>",
"      The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"       midodrine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H206033818\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many factors may contribute to hypotension occurring during hemodialysis. These include a rapid reduction in plasma osmolality, rapid fluid removal, an inaccurate determination of dry weight, presence of autonomic neuropathy or decreased myocardial function, intake of antihypertensive medications, and other factors. Infrequently, patients have a serious condition that requires immediate attention, such as arrhythmias, pericardial tamponade, myocardial infarction, as well as other conditions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with dialysis-induced hypotension may be asymptomatic or present with symptoms, including light-headedness, muscle cramps,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      and dyspnea. Acute management of this condition includes either stopping or decreasing ultrafiltration, placing the patient in the Trendelenburg position, reducing the blood flow rate, and replacing intravascular volume with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"       mannitol",
"      </a>",
"      or saline. Further treatment is based upon the etiology of the hypotension. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A significant number of measures have been evaluated to help prevent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      reduce the incidence of symptomatic dialysis hypotension. These include exclusion of non-dialysis related causes, variations in the dialysis prescription and approach to ultrafiltration, as well as other approaches. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prevention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Recommendations for prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/1\">",
"      Orofino L, Marc&eacute;n R, Quereda C, et al. Epidemiology of symptomatic hypotension in hemodialysis: is cool dialysate beneficial for all patients? Am J Nephrol 1990; 10:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/2\">",
"      Henrich WL. Hemodynamic instability during hemodialysis. Kidney Int 1986; 30:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/3\">",
"      van der Sande FM, Kooman JP, Leunissen KM. Intradialytic hypotension--new concepts on an old problem. Nephrol Dial Transplant 2000; 15:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/4\">",
"      Flythe JE, Kunaparaju S, Dinesh K, et al. Factors associated with intradialytic systolic blood pressure variability. Am J Kidney Dis 2012; 59:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/5\">",
"      Kouw PM, Kooman JP, Cheriex EC, et al. Assessment of postdialysis dry weight: a comparison of techniques. J Am Soc Nephrol 1993; 4:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/6\">",
"      B&eacute;gin V, D&eacute;ziel C, Madore F. Biofeedback regulation of ultrafiltration and dialysate conductivity for the prevention of hypotension during hemodialysis. ASAIO J 2002; 48:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/7\">",
"      Brennan JM, Ronan A, Goonewardena S, et al. Handcarried ultrasound measurement of the inferior vena cava for assessment of intravascular volume status in the outpatient hemodialysis clinic. Clin J Am Soc Nephrol 2006; 1:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/8\">",
"      Nette RW, van den Dorpel MA, Krepel HP, et al. Hypotension during hemodialysis results from an impairment of arteriolar tone and left ventricular function. Clin Nephrol 2005; 63:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/9\">",
"      Shinzato T, Miwa M, Nakai S, et al. Role of adenosine in dialysis-induced hypotension. J Am Soc Nephrol 1994; 4:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/10\">",
"      Barakat MM, Nawab ZM, Yu AW, et al. Hemodynamic effects of intradialytic food ingestion and the effects of caffeine. J Am Soc Nephrol 1993; 3:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/11\">",
"      Noris M, Benigni A, Boccardo P, et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/12\">",
"      Yokokawa K, Mankus R, Saklayen MG, et al. Increased nitric oxide production in patients with hypotension during hemodialysis. Ann Intern Med 1995; 123:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/13\">",
"      Roy, PN, Danziger, RS. Dialysate magnesium concentration predicts the occurrence of intradialytic hypotension (abstract). J Am Soc Nephrol 1996; 7:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/14\">",
"      van der Zee S, Thompson A, Zimmerman R, et al. Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int 2007; 71:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/15\">",
"      Masani NN, Miyawaki N, Maesaka JK. A patient with an uncommon etiology of intradialytic hypotension. Semin Dial 2005; 18:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/16\">",
"      Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004; 66:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/17\">",
"      Chang TI, Paik J, Greene T, et al. Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol 2011; 22:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/18\">",
"      McIntyre CW. Recurrent circulatory stress: the dark side of dialysis. Semin Dial 2010; 23:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/19\">",
"      Emili S, Black NA, Paul RV, et al. A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients. Am J Kidney Dis 1999; 33:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/20\">",
"      Knoll GA, Grabowski JA, Dervin GF, O'Rourke K. A randomized, controlled trial of albumin versus saline for the treatment of intradialytic hypotension. J Am Soc Nephrol 2004; 15:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/21\">",
"      Letteri, JM. Symptomatic hypotension during hemodialysis. Semin Dial 1998; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/22\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/23\">",
"      Merino JL, Rivera M, Teruel JL, et al. CAPD as treatment of chronic debilitating hemodialysis hypotension. Perit Dial Int 2002; 22:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/24\">",
"      Donauer J, K&ouml;lblin D, Bek M, et al. Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects. Am J Kidney Dis 2000; 36:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/25\">",
"      D&eacute;ziel C, Bouchard J, Zellweger M, Madore F. Impact of hemocontrol on hypertension, nursing interventions, and quality of life: a randomized, controlled trial. Clin J Am Soc Nephrol 2007; 2:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/26\">",
"      Basile C, Vernaglione L, Di Iorio B, et al. Development and validation of bioimpedance analysis prediction equations for dry weight in hemodialysis patients. Clin J Am Soc Nephrol 2007; 2:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/27\">",
"      Palmer BF, Henrich WL. Recent advances in the prevention and management of intradialytic hypotension. J Am Soc Nephrol 2008; 19:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/28\">",
"      Kraemer M, Rode C, Wizemann V. Detection limit of methods to assess fluid status changes in dialysis patients. Kidney Int 2006; 69:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/29\">",
"      van de Pol AC, Frenken LA, Moret K, et al. An evaluation of blood volume changes during ultrafiltration pulses and natriuretic peptides in the assessment of dry weight in hemodialysis patients. Hemodial Int 2007; 11:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/30\">",
"      Kuhlmann MK, Zhu F, Seibert E, Levin NW. Bioimpedance, dry weight and blood pressure control: new methods and consequences. Curr Opin Nephrol Hypertens 2005; 14:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/31\">",
"      Daugirdas, JT. Preventing and managing hypotension. Semin Dial 1994; 7:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/32\">",
"      Stiller S, Bonnie-Schorn E, Grassmann A, et al. A critical review of sodium profiling for hemodialysis. Semin Dial 2001; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/33\">",
"      Locatelli F, Covic A, Chazot C, et al. Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant 2004; 19:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/34\">",
"      Sang GL, Kovithavongs C, Ulan R, Kjellstrand CM. Sodium ramping in hemodialysis: a study of beneficial and adverse effects. Am J Kidney Dis 1997; 29:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/35\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/36\">",
"      Song JH, Park GH, Lee SY, et al. Effect of sodium balance and the combination of ultrafiltration profile during sodium profiling hemodialysis on the maintenance of the quality of dialysis and sodium and fluid balances. J Am Soc Nephrol 2005; 16:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/37\">",
"      Jacob AD, Elkins N, Reiss OK, et al. Effects of acetate on energy metabolism and function in the isolated perfused rat heart. Kidney Int 1997; 52:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/38\">",
"      Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/39\">",
"      van der Sande FM, Rosales LM, Brener Z, et al. Effect of ultrafiltration on thermal variables, skin temperature, skin blood flow, and energy expenditure during ultrapure hemodialysis. J Am Soc Nephrol 2005; 16:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/40\">",
"      Maggiore Q, Pizzarelli F, Santoro A, et al. The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 2002; 40:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/41\">",
"      Schneditz D, Ronco C, Levin N. Temperature control by the blood temperature monitor. Semin Dial 2003; 16:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/42\">",
"      P&eacute;rgola PE, Habiba NM, Johnson JM. Body temperature regulation during hemodialysis in long-term patients: is it time to change dialysate temperature prescription? Am J Kidney Dis 2004; 44:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/43\">",
"      Karamperis N, Sloth E, Jensen JD. Predilution hemodiafiltration displays no hemodynamic advantage over low-flux hemodialysis under matched conditions. Kidney Int 2005; 67:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/44\">",
"      Poldermans D, Man in 't Veld AJ, Rambaldi R, et al. Cardiac evaluation in hypotension-prone and hypotension-resistant hemodialysis patients. Kidney Int 1999; 56:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/45\">",
"      Alappan R, Cruz D, Abu-Alfa AK, et al. Treatment of Severe Intradialytic Hypotension With the Addition of High Dialysate Calcium Concentration to Midodrine and/or Cool Dialysate. Am J Kidney Dis 2001; 37:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/46\">",
"      Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am J Kidney Dis 1999; 33:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/47\">",
"      Flynn JJ 3rd, Mitchell MC, Caruso FS, McElligott MA. Midodrine treatment for patients with hemodialysis hypotension. Clin Nephrol 1996; 45:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/48\">",
"      Montagnac R, Clavel P, Delhotal-Landes B, et al. Use of midodrine (Gutron) to treat permanent hypotension in a chronic hemodialysis patient. Clin Nephrol 2001; 56:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/49\">",
"      Perazella MA. Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis 2001; 38:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/50\">",
"      Prakash S, Garg AX, Heidenheim AP, House AA. Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review. Nephrol Dial Transplant 2004; 19:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/51\">",
"      Imai E, Fujii M, Kohno Y, et al. Adenosine A1 receptor antagonist improves intradialytic hypotension. Kidney Int 2006; 69:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31240/abstract/52\">",
"      Dheenan S, Henrich WL. Preventing dialysis hypotension: a comparison of usual protective maneuvers. Kidney Int 2001; 59:1175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1945 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31240=[""].join("\n");
var outline_f30_32_31240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H206033818\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H441018086\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Accurate setting of the \"dry weight\"",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Steady, constant ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased dialysate sodium concentration and sodium modeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Combination sodium modeling and ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sequential ultrafiltration and isovolemic dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bicarbonate dialysate buffer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Temperature control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Improvement in cardiovascular performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Midodrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Carnitine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Avoidance of food",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adenosine release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Vasopressin infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Comparative efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Recommendations for prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H206033818\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1945\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1945|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/31/3582\" title=\"figure 1\">",
"      Water shifts in hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/4/3150\" title=\"figure 2\">",
"      Water shifts hemofiltration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/16/23816?source=related_link\">",
"      Arteriovenous fistulas and grafts for chronic hemodialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19684?source=related_link\">",
"      Autonomic dysfunction in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14200?source=related_link\">",
"      Carnitine metabolism in renal disease and dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24690?source=related_link\">",
"      Cool temperature hemodialysis: Hemodynamic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/115?source=related_link\">",
"      Overview of the hemodialysis apparatus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31241="Management of chylothorax";
var content_f30_32_31241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of chylothorax",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31241/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31241/contributors\">",
"     John E Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31241/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31241/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/32/31241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1066254\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylothorax is caused by disruption or obstruction of the thoracic duct or its tributaries that results in leakage of chyle (lymphatic fluid of intestinal origin) into the pleural space. Chylous ascites can also flow into the pleural space. The fluid typically has a high triglyceride content and often a turbid or milky white appearance. In contrast, a cholesterol pleural effusion, which can also have a milky appearance, has a high concentration of cholesterol and lecithin-globulin complexes that accumulate due to pleural inflammation or infection.",
"   </p>",
"   <p>",
"    A pleural fluid triglyceride concentration greater than 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.24",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    strongly supports the diagnosis of a chylothorax, but triglyceride concentrations may be less than 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in 15 percent of patients and less than 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/1\">",
"     1",
"    </a>",
"    ]. Detection of chylomicrons in the pleural fluid by lipoprotein analysis confirms the presence of a chylothorax when the triglyceride level is less than 110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (less than 1.24",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and the diagnosis is suspected clinically.",
"   </p>",
"   <p>",
"    The therapeutic options and an approach to managing chylothorax will be reviewed here. The etiology, clinical presentation, and diagnosis of chylothorax, the evaluation and management of cholesterol effusions, and general issues regarding the evaluation and treatment of pleural effusions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31448?source=see_link\">",
"     \"Clinical presentation, diagnosis and management of cholesterol effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=see_link\">",
"     \"Mechanisms of pleural liquid accumulation in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067364\">",
"    <span class=\"h1\">",
"     THERAPEUTIC OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of interventions have been used to treat chylothorax, including treatment of the underlying disease, pleural drainage, dietary modifications, pleurodesis, and thoracic duct ligation. More rarely used modalities include",
"    <span class=\"nowrap\">",
"     somatostatin/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"      octreotide",
"     </a>",
"     ,",
"    </span>",
"    pleurovenous or pleuroperitoneal shunting, and thoracic duct embolization. Staged approaches for using the various options based on the etiology of the chylothorax are discussed in the following sections. (See",
"    <a class=\"local\" href=\"#H1067428\">",
"     'Management approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067371\">",
"    <span class=\"h2\">",
"     Treatment of the underlying condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with chylothorax due to nontraumatic causes, such as infection, sarcoidosis, lymphoma, and metastatic carcinoma, treatment of the underlying condition is an important component of therapy, either alone or combined with other modalities depending on the severity of chyle leakage and rapidity of response to therapy. (See",
"    <a class=\"local\" href=\"#H1067435\">",
"     'Nontraumatic chylothorax'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067379\">",
"    <span class=\"h2\">",
"     Pleural drainage to control symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent therapeutic thoracentesis or use of an indwelling catheter for home drainage are typically used in the initial management of nontraumatic and nonsurgical traumatic effusions to relieve dyspnea caused by lung compression from pleural fluid. These techniques are usually employed in outpatients who have a gradual reaccumulation of pleural fluid and will often control respiratory symptoms over the short-term while waiting for the chyle leak to resolve with conservative therapy.",
"   </p>",
"   <p>",
"    Chest tube placement is typically performed in patients with a postsurgical chylothorax or in those with chylothoraces that rapidly reaccumulate. However, long-term, continuous chest tube drainage is associated with an increased risk of infections, as well as electrolyte and nutritional losses [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. As an example, when thoracic duct drainage is used to deplete lymphocytes and prepare patients for organ transplantation, 14 days of chylous drainage results in a clinically important degree of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, continuous pleural fluid drainage by chest tube is generally limited to 14 days to minimize the risk of infection. Surgical intervention is generally indicated sooner (eg, within seven days), if the drainage of pleural fluid exceeds 1 to 1.5",
"    <span class=\"nowrap\">",
"     liter/day,",
"    </span>",
"    or if the drainage of chyle results in weight loss and progressive hypoproteinemia despite aggressive nutritional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients managed with continuous drainage of chylous pleural fluid require monitoring of serum electrolytes, lymphocyte counts, albumin, total protein, and weight. Depending on the drainage rate, patients may require blood tests two to three times a week until they maintain stable values. &nbsp;Patients who undergo complete fasting in addition to continuous drainage require",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    designed to offset the protein and calorie losses related to drainage of the chylothorax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=see_link\">",
"     \"Nutritional support in advanced lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067386\">",
"    <span class=\"h2\">",
"     Dietary control measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasting or a reduced fat diet decrease the flow of chyle through the thoracic duct and allow spontaneous closure of a thoracic duct leak. Dietary exclusion of long-chain triglycerides (LCT) avoids their conversion into monoglycerides and free fatty acids (FFA), which are transported as chylomicrons to the intestinal lymph ducts. A reduced fat diet may be supplemented with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    (MCTs), which are absorbed directly into intestinal cells and transported directly to the liver via the portal vein, thus bypassing the thoracic duct [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. MCTs are commercially available as MCT Oil (Mead Johnson, USA). The usual initial oral adult dose of MCT oil for use as a nutritional supplement is 1 tablespoon three to four times per day. Common adverse effects are nausea, occasional vomiting, abdominal pain, and diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/10/168?source=see_link&amp;anchor=H15#H15\">",
"     \"Chylous, bloody, and pancreatic ascites\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is controversial whether complete discontinuation of enteral feedings results in a greater decrease in chyle flow than modified enteral nutrition (high protein-low fat diet) supplemented with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    (MCTs) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. No comparative studies have been performed, and variable results have been described in case series. Results may be influenced by the rate of chyle leakage, exact MCTs used, and degree of compliance with the reduced fat diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067400\">",
"    <span class=\"h2\">",
"     Pleurodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis is often performed in patients whose chylothorax has not responded to thoracentesis and dietary control measures. Options include talc instillation at the bedside, talc insufflation during video-assisted thoracoscopy, other forms of chemical pleurodesis, and mechanical pleurodesis at the time of thoracoscopy or thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The details of chemical pleurodesis and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=see_link\">",
"     \"Talc pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The success of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    generally depends on adequate drainage of the pleural space prior to instillation or insufflation of talc, such that high output chylothoraces may require concomitant thoracic duct ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. It is difficult to determine the relative success of pleurodesis alone versus pleurodesis plus thoracic duct ligation, as the available data is limited to case series, which may be biased (eg, the rate of chyle output may have influenced the choice of procedure) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/18\">",
"     18",
"    </a>",
"    ]. Nonetheless, series of patients who underwent pleurodesis alone for nonsurgical chylothorax generally reveal a success rate between 80 and 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/16,18-20\">",
"     16,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minimal data are available regarding pleurodesis for postsurgical chylothorax; small series and case reports have reported a few successes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    without thoracic duct ligation, as thoracic duct ligation is generally considered the treatment of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1067463\">",
"     'Postoperative (surgical) chylothorax'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067407\">",
"    <span class=\"h2\">",
"     Thoracic duct ligation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who require thoracic duct ligation have a high volume chylothorax, which occurs most commonly as a complication of a surgical procedure such as esophagectomy or lung resection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Thoracic duct ligation is performed via video-assisted thoracoscopy or open thoracotomy depending on local expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/23-29\">",
"     23-29",
"    </a>",
"    ]. Some surgeons prefer an open approach (eg, thoracotomy) for greater visibility in patients who have a postsurgical chylothorax, although this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Access to the thoracic duct is usually via the side with the chylothorax, as that side is typically the location of the thoracic duct tear. In addition, accessing the side with the chylothorax allows mechanical or chemical pleurodesis to be performed on that side during the operation. However, other considerations regarding the surgical approach may influence the choice of which side to enter, such as the exact course of the thoracic duct in that patient, the side of the initial surgery, and the ease or difficulty of a left-sided approach in patients who have a gastric conduit following esophagectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link&amp;anchor=H19#H19\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'VATS pleurodesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To help identify the leakage site, dairy cream or another fat load mixed with a lipophilic green dye may be administered via nasogastric or nasojejunal tube 20 minutes prior to induction of anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/27\">",
"     27",
"    </a>",
"    ]. Alternatively, as the leakage site is often apparent without this step, the cream or enteral fat load may be administered intraoperatively when needed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/25\">",
"     25",
"    </a>",
"    ]. In some centers, lymphangiography is performed prior to surgery to identify the site of leakage, although the degree to which this procedure improves surgical success is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/18,30,31\">",
"     18,30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link&amp;anchor=H10472849#H10472849\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\", section on 'Lymphangiography and lymphoscintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During thoracic duct ligation, sutures are placed on both sides of an identified tear; when the exact leakage site is unclear, the duct is usually ligated just cephalad to the aortic hiatus [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. In addition, a sealant or fibrin glue is sometimes applied to the area of ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/32\">",
"     32",
"    </a>",
"    ]. Extensive dissection to identify the site of leakage is discouraged as this may lead to creation of additional thoracic duct leakage sites [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphedema is a known complication of thoracic duct ligation, but usually resolves over several months as collateral lymphatic-venous communications develop [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the chyle leak is determined to be subdiaphragmatic based on thoracoscopic examination or lymphatic imaging, a laparoscopic approach is used to ligate the cisterna chyli (a sac at the caudal or lower end of the thoracic duct into which the intestinal and two lumbar lymphatic trunks drain). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link&amp;anchor=H3#H3\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\", section on 'Anatomy of the thoracic duct'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7911741\">",
"    <span class=\"h2\">",
"     Infrequently used therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies, such as",
"    <span class=\"nowrap\">",
"     somatostatin/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"      octreotide",
"     </a>",
"     ,",
"    </span>",
"    pleurovenous and pleuroperitoneal shunting, and thoracic duct embolization, have been used in small numbers of patients and are typically employed when the therapies described above have been unsuccessful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17078932\">",
"    <span class=\"h3\">",
"     Somatostatin and octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , a somatostatin analogue that has a longer half-life in the circulation, are thought to act on somatostatin receptors to reduce the flow rate of thoracic duct lymph, to decrease the volume of fluid within the thoracic duct by inhibiting gastric, pancreatic, and biliary secretions, and to inhibit absorption from the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Because of the reduction in chyle production and flow rate, these agents have been used in case reports and case series to treat spontaneous chylothorax, congenital chylothorax, postoperative chylothorax, and chylothorax due to malignancy and yellow nail syndrome, sometimes in combination with a reduced fat diet supplemented with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/35-43\">",
"     35-43",
"    </a>",
"    ]. Use of these agents in the management of chylothorax remains experimental, pending further studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=see_link\">",
"     \"Physiology of somatostatin and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported doses of somatostatin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    for treatment of chylothorax vary and the optimal dose and route of administration are not known. In a series of adult patients, somatostatin was given by intravenous infusion 6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for two weeks or by subcutaneous injection, 50 microg every eight hours; octreotide was given in subcutaneous doses of 50 to 100 microg every eight hours for 2 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/33\">",
"     33",
"    </a>",
"    ]. In a systematic review of pediatric cases, somatostatin was given as an intravenous infusion at a median dose of 204",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per day, for a median duration of 9.5 days, and octreotide was given as an intravenous infusion at a median dose of 68",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per day for a median seven days, or subcutaneously at a median dose of 40",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per day for a median duration of 17 days [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of 35 children with primary or secondary chylothorax who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    or somatostatin, a positive treatment effect was apparent after five days in all 25 children who received octreotide and in nine of the ten children who received somatostatin [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/42\">",
"     42",
"    </a>",
"    ]. Minor side effects included flu-like symptoms, cutaneous flushing, nausea, diarrhea, transaminitis, transient abdominal distension, transient hyperthyroidism, and hyperglycemia. Two children developed serious side effects: one child with aortic coarctation developed necrotizing enterocolitis and one child with asplenia syndrome developed strangulation-ileus.",
"   </p>",
"   <p>",
"    In general, side effects of somatostatin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    include cutaneous flushing, nausea, diarrhea, sinus bradycardia, injection site pain, transient hypothyroidism, and elevated liver function tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067414\">",
"    <span class=\"h3\">",
"     Pleuroperitoneal or pleurovenous shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleurovenous and pleuroperitoneal shunting of chylous pleural fluid are occasionally used after failure of pleurodesis or thoracic duct ligation or for those who have failed conservative management but are poor candidates for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/13,20,44-47\">",
"     13,20,44-47",
"    </a>",
"    ]. Two types of pleuroperitoneal shunt are available, an active version that requires frequent activation of a manual pump (Denver pleuroperitoneal shunt) and a passive version (LeVeen pleuroperitoneal shunt) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/45\">",
"     45",
"    </a>",
"    ]. These shunting procedures recycle the nutritionally important constituents of chyle and avoid more invasive surgery.",
"   </p>",
"   <p>",
"    Pleurovenous shunting of chylous fluid from the pleural space to the subclavian or jugular vein has been successful in isolated patients with lymphangioleiomyomatosis, yellow nail syndrome, and postsurgical chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/44,46,47\">",
"     44,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleuroperitoneal shunting was successful in a patient with a refractory high-volume chylothorax that developed after transhiatal esophagectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/45\">",
"     45",
"    </a>",
"    ]. &nbsp;On the other hand, it was unsuccessful in a patient with yellow nail syndrome who developed worsening abdominal distention and lower extremity edema; however, pleurovenous shunting was successful in that patient [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pleuroperitoneal shunting is not useful in patients with chylothorax due to chylous ascites, due to transdiaphragmatic communications.",
"   </p>",
"   <p>",
"    Complications of pleuroperitoneal and pleurovenous shunts include shunt occlusion, infection, and migration of the shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067421\">",
"    <span class=\"h3\">",
"     Thoracic duct embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous catheterization and embolization of the thoracic duct has been employed in patients with postoperative chylothoraces, but is only available in selected centers [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/48-53\">",
"     48-53",
"    </a>",
"    ]. Initial pedal lymphangiography allows fluoroscopic visualization of large retroperitoneal lymphatics, which are then cannulated percutaneously and injected with surgical &ldquo;glue&rdquo; with or without endovascular coils or particles [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/48,54\">",
"     48,54",
"    </a>",
"    ]. The procedure is technically challenging and catheterization of the thoracic duct is only successful in approximately 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/54\">",
"     54",
"    </a>",
"    ]. When the thoracic duct is successfully catheterized and embolized, the success rate for resolution of chylothorax is 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link&amp;anchor=H10472849#H10472849\">",
"     \"Etiology, clinical presentation, and diagnosis of chylothorax\", section on 'Lymphangiography and lymphoscintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with this technique is limited and trials comparing it to thoracic duct ligation have not been performed. Complications include lower extremity edema, pedal wound dehiscence and infection, and embolization of the surgical &ldquo;glue&rdquo; to the pulmonary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/48,52,54\">",
"     48,52,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067428\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of a chylothorax is unclear because no prospective studies exist to guide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/6\">",
"     6",
"    </a>",
"    ]. Our treatment approach is based on clinical experience and data from case reports and case series. The exact steps vary depending on the etiology of the chylothorax, the rate of accumulation, local expertise with various procedures, and the response to initial therapy. Three principles, however, are followed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients benefit from a staged care plan that moves from least invasive options to surgical intervention and includes thoracentesis, treatment of the underlying condition (eg, infection, sarcoidosis, lymphoma), dietary control measures, chemical pleurodesis, surgical pleurodesis, and thoracic duct ligation. Combinations of these therapies are often employed and sometimes less well studied therapies (eg, somatostatin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      therapy, shunting, thoracic duct embolization) are used for patients with atypical presentations.",
"     </li>",
"     <li>",
"      Patients with large volume drainage (&gt;1 L per day) of chylous fluid through the chest tube will most likely require early, surgical intervention. High output chylothoraces are most common in postsurgical patients and those with liver cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolonged chest tube drainage of a chylothorax (eg, more than two weeks) should be avoided to prevent patients from becoming immunosuppressed and malnourished, which would decrease their tolerance of definitive surgical therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067435\">",
"    <span class=\"h2\">",
"     Nontraumatic chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in management of a nontraumatic chylothorax is treatment of the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/22,28,55,56\">",
"     22,28,55,56",
"    </a>",
"    ]. As examples, patients with chylothorax due to underlying sarcoidosis may respond to glucocorticoid therapy; those with underlying lymphoma or metastatic cancer frequently respond to therapy directed at the primary tumor or metastatic sites. Therapeutic thoracentesis or an indwelling pleural catheter may be used to control dyspnea during initial treatment of the underlying disease. The subsequent decisions on whether to pursue pleurodesis or thoracic duct ligation depend on the response to initial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067442\">",
"    <span class=\"h3\">",
"     Malignant chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment of a malignant chylothorax includes therapeutic thoracentesis for relief of dyspnea and treatment of the underlying malignancy. Treatment of the underlying malignancy with chemotherapy and irradiation has yielded mixed results in terms of resolution of the chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/22,28,55,57-59\">",
"     22,28,55,57-59",
"    </a>",
"    ]. Among patients with lymphoma, resolution of chylothorax with chemotherapy or radiation ranges from 25 to 70 percent depending on the series [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a symptomatic, malignant chylothorax that fails to resolve after treatment of the underlying condition, we suggest instillation of a pleural sclerosing agent (such as talc) through a chest tube or thoracoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Chemical pleurodesis is favored over surgical ligation of the thoracic duct as malignant chylothorax does not usually benefit from ligation of the thoracic duct and bedside pleurodesis is less invasive [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/60\">",
"     60",
"    </a>",
"    ]. Small case series of patients with malignant chylothorax have found a high success rate with pleurodesis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/19,61\">",
"     19,61",
"    </a>",
"    ], although failures have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/18,62\">",
"     18,62",
"    </a>",
"    ]. Insufflation of talc through a thoracoscope has been reported to control chylothoraces from lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/19\">",
"     19",
"    </a>",
"    ]. The details of chemical and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    are provided separately. (See",
"    <a class=\"local\" href=\"#H1067400\">",
"     'Pleurodesis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=see_link\">",
"     \"Talc pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of malignant pleural effusions\", section on 'Rapid reaccumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have a recurrent malignant chylothorax despite the above measures, other techniques may be performed depending on local expertise, such as the long-term use of an indwelling pleural catheter or placement of pleuroperitoneal [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/63\">",
"     63",
"    </a>",
"    ] or pleurovenous shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/44\">",
"     44",
"    </a>",
"    ]. A retrospective case control study of 10 patients with malignant chylothorax found a favorable response to outpatient use of an indwelling pleural catheter, compared to alternative strategies, such as repeated thoracenteses, a pleuroperitoneal shunt, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    (one patient) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1067414\">",
"     'Pleuroperitoneal or pleurovenous shunt'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A small case series (7 patients) and isolated case reports have described successful management of malignant chylothorax using subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    and a fat-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/40\">",
"     40",
"    </a>",
"    ]. This may be a reasonable option for patients who are not surgical candidates, although further study is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/22,38,40\">",
"     22,38,40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17078932\">",
"     'Somatostatin and octreotide'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067449\">",
"    <span class=\"h3\">",
"     Idiopathic and benign chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with benign causes of chylothorax (eg, lupus, infection, sarcoidosis, cirrhosis) may respond to medical therapy directed at their underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/22,56\">",
"     22,56",
"    </a>",
"    ]. In the meantime, those who are symptomatic due to an idiopathic or benign chylothorax are managed with \"conservative\" therapy with chest tube drainage and dietary control measures to limit the flow of chyle. Dietary regimens include a high protein-low fat diet with limited oral intake, supplemented with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    (MCT), or fasting plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/8,13,18,65\">",
"     8,13,18,65",
"    </a>",
"    ]. Patients with more slowly accumulating chylothorax may wish to try the high protein-reduced fat oral diet first and implement fasting and total parenteral nutrition if the chylothorax is not controlled with the enteral diet. Conservative measures are successful in approximately 40 to 80 percent, depending on the case series [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/18,25,65\">",
"     18,25,65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1067386\">",
"     'Dietary control measures'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    More aggressive therapy is warranted if a symptomatic idiopathic or benign chylothorax persists for more than two weeks despite these measures, or sooner if the fluid output exceeds 1",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/27,55\">",
"     27,55",
"    </a>",
"    ]. Treatment options include chemical pleurodesis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/15-18,66\">",
"     15-18,66",
"    </a>",
"    ], decortication (pleurectomy), oversewing of the thoracic duct disruption and any leaking collaterals, and also ligation of the thoracic duct at the aortic hiatus [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. We typically perform thoracic duct ligation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    at the time of video-assisted thoracoscopy, as this combination appears to have the highest likelihood of success [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. If a thoracic duct tear is visible and amenable to repair or application of fibrin glue, repair of the duct may be attempted [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/47\">",
"     47",
"    </a>",
"    ]. We reserve decortication for patients who have failed prior thoracic duct ligation and pleurodesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=see_link\">",
"     \"Talc pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175735500\">",
"    <span class=\"h2\">",
"     Traumatic chylothorax",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1067463\">",
"    <span class=\"h3\">",
"     Postoperative (surgical) chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;When managing a postoperative chylothorax, we follow a stepwise approach that is based on clinical experience and data from case series. Initial management includes chest tube drainage to monitor output and reduce dyspnea and dietary control measures to reduce chyle flow. We usually implement complete fasting with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN), but others may use a high protein- low fat diet with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    (MCT) supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/9,24,65,71,72\">",
"     9,24,65,71,72",
"    </a>",
"    ]. Complete fasting was associated with slightly better results than a modified enteral diet in case series, although randomized trials have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/65\">",
"     65",
"    </a>",
"    ]. As an example, in a series of 26 postsurgical patients, chylothorax responded to conservative management (complete fasting and TPN) in 81 percent, while in two smaller series conservative therapy (either fast with TPN or reduced fat enteral diet with MCT) was successful in 23 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/24,67,71\">",
"     24,67,71",
"    </a>",
"    ]. Overall, conservative management has approximately a 50 percent success rate in postoperative chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/18,25\">",
"     18,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term chest tube drainage of a chylothorax is associated with nutritional depletion and high mortality rates, so we generally proceed to surgical intervention if the chylothorax has not responded to conservative management within 5 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. The exact timing of surgical intervention is influenced by a number of factors, such as the rate of chyle drainage, the likelihood of response to conservative therapy, and the risk of further surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/67,71\">",
"     67,71",
"    </a>",
"    ]. The following observations guide our decision-making process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mortality rate of postoperative chylothorax approached 50 percent prior to implementation of ligation of the thoracic duct [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/27,73\">",
"       27,73",
"      </a>",
"      ]. Since implementation of this technique, mortality has decreased to 10 percent or less. Thoracic duct ligation for postoperative chylothorax is associated with a 90 percent success rate [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/18,20\">",
"       18,20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1067407\">",
"       'Thoracic duct ligation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients draining more than 1",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      are unlikely to respond to conservative therapy and usually require surgical intervention within 5 to 7 days [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/74\">",
"       74",
"      </a>",
"      ]. In contrast, patients with less than 500 mL of chest tube drainage in the first 24 hours after cessation of oral intake and initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      tend to improve with conservative management [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a chylothorax after resection of a malignancy, such as esophageal cancer, are less likely to respond to conservative therapy because they are often leaking chyle from lymphatic collaterals that seldom heal spontaneously. Earlier surgical intervention (eg, one week or less) to achieve more rapid resolution of chyle drainage may prevent nutritional depletion and immune compromise from chyle losses, if the patient is able to tolerate a second surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/67,75,76\">",
"       67,75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Younger adult patients at low risk for additional postoperative complications may prefer to undergo earlier surgical repair in order to shorten their hospital stay, rather than continuing with conservative therapy for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175735402\">",
"    <span class=\"h3\">",
"     Postpneumonectomy chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a chylothorax in a postpneumonectomy space are treated with dietary control measures",
"    <strong>",
"     without",
"    </strong>",
"    chest tube drainage unless the mediastinum shifts back toward the midline. Shift of the mediastinum back to the midline suggests development of tension chylothorax, which requires urgent placement of a chest tube, followed by surgery, either thoracotomy or thoracoscopy, to gain control of the lymphatic leak [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Thoracoscopic application of fibrin glue to the site of leakage has been used successfully.",
"   </p>",
"   <p>",
"    When chylothorax occurs after lung transplantation, particularly when performed for pulmonary lymphangiomyomatosis, it is often refractory to conservative therapy. A spectrum of therapies has been tried, including thoracic duct ligation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    injections,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    administration, and pleurovenous shunting. (See",
"    <a class=\"local\" href=\"#H17078932\">",
"     'Somatostatin and octreotide'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1067414\">",
"     'Pleuroperitoneal or pleurovenous shunt'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32103?source=see_link&amp;anchor=H10#H10\">",
"     \"The pleura in lung transplantation\", section on 'Chylothorax'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88586908\">",
"    <span class=\"h3\">",
"     Nonsurgical traumatic chylothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of a symptomatic chylothorax induced by nonsurgical trauma usually includes chest tube placement, maintenance of fluid and electrolyte balance, and bowel rest with parenteral nutrition to minimize the flow of thoracic duct chyle. If patients are able to tolerate enteral feeds, a high protein-low fat diet supplemented with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"     medium chain triglycerides",
"    </a>",
"    is an alternative to complete fasting, although data to support this option are lacking.",
"   </p>",
"   <p>",
"    Chest tube drainage of the pleural space combined with dietary control measures to reduce chyle flow is successful in allowing the leak in the thoracic duct to close spontaneously in approximately 50 percent of patients with nonsurgical traumatic chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/18\">",
"     18",
"    </a>",
"    ]. If chyle continues to drain from the chest tube, a surgical intervention is usually necessary.",
"   </p>",
"   <p>",
"    Selection of a surgical approach depends upon local surgical expertise and preference, and data regarding the relative benefits of the different interventions in these patients are limited. The decision regarding when to intervene surgically is derived from the experience with postsurgical chylothorax (eg, drainage longer than 14 days, greater than",
"    <span class=\"nowrap\">",
"     1L/day",
"    </span>",
"    drainage for 5 or more days). When surgical intervention is needed based on the amount and duration of chyle drainage, most centers ligate the thoracic duct above the aortic hiatus and attempt to repair or ligate lymphatic collaterals at sites of disruption. Chemical pleurodesis may be performed at the time of thoracic duct ligation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31241/abstract/25,27-29\">",
"     25,27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=see_link\">",
"     \"Chemical pleurodesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1069952\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chylothorax is caused by disruption of the thoracic duct or its tributaries that results in leakage of chyle (lymphatic fluid of intestinal origin) into the pleural space. Chylous ascites can also flow to the pleural space causing a chylothorax. The diagnosis is based on a pleural fluid triglyceride concentration greater than 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.24",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or the presence of chylomicrons in the pleural fluid when the triglyceride level is less than 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.24",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and chylothorax remains suspected clinically. (See",
"      <a class=\"local\" href=\"#H1066254\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31448?source=see_link\">",
"       \"Clinical presentation, diagnosis and management of cholesterol effusions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The table provides a list of the most common etiologies of chylothorax (",
"      <a class=\"graphic graphic_table graphicRef61456 \" href=\"UTD.htm?32/27/33212\">",
"       table 1",
"      </a>",
"      ). The management of chylothorax varies depending on the etiology of the chylothorax, the rate of accumulation, local expertise with various procedures, and the response to initial therapy. No management algorithm has been universally adopted. Most patients benefit from a staged care plan that moves gradually from least invasive to progressively more invasive options although some etiologies of chylothorax warrant early definitive therapy to avoid nutritional depletion. Combinations of therapies are often employed. (See",
"      <a class=\"local\" href=\"#H1067428\">",
"       'Management approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=see_link&amp;anchor=H5#H5\">",
"       \"Etiology, clinical presentation, and diagnosis of chylothorax\", section on 'Etiology of chylothorax'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a nontraumatic chylothorax due to an underlying disease that is amenable to medical therapy or irradiation (eg, infection, sarcoidosis, lymphoma), we initiate prompt treatment of the underlying disease. (See",
"      <a class=\"local\" href=\"#H1067435\">",
"       'Nontraumatic chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a nontraumatic chylothorax (eg, malignant, idiopathic, sarcoidosis, lymphangioleiomyomatosis) is large enough to cause respiratory compromise (eg, dyspnea at rest or with minimal exertion), we recommend initial therapeutic pleural drainage rather than more invasive options (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Pleural drainage may be accomplished by therapeutic thoracentesis, tube thoracostomy, or indwelling pleural catheter placement, depending on the rate of accumulation and the anticipated response to therapy. (See",
"      <a class=\"local\" href=\"#H1067379\">",
"       'Pleural drainage to control symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067435\">",
"       'Nontraumatic chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nontraumatic, nonmalignant chylothorax, we also suggest a trial of dietary control measures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), which include fasting plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      or a high protein-low fat diet, supplemented with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/51/19250?source=see_link\">",
"       medium chain triglycerides",
"      </a>",
"      (MCT). The latter option is most commonly used for patients who have a slower rate of accumulation and are not nutritionally depleted already. (See",
"      <a class=\"local\" href=\"#H1067435\">",
"       'Nontraumatic chylothorax'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067386\">",
"       'Dietary control measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a symptomatic malignant chylothorax that fails to resolve after treatment of the underlying condition and accumulates sufficiently rapidly to make intermittent thoracentesis burdensome, we suggest instillation of a pleural sclerosing agent (such as talc) through a chest tube or thoracoscope (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Alternatives would include surgical thoracic duct ligation in addition to pleurodesis for those who are able to tolerate surgery or use of an indwelling pleural catheter for intermittent drainage or addition of somatostatin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      (which remain experimental for this indication) for those who are not surgical candidates. (See",
"      <a class=\"local\" href=\"#H1067442\">",
"       'Malignant chylothorax'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of malignant pleural effusions\", section on 'Rapid reaccumulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For most patients with an idiopathic or benign nontraumatic chylothorax that is refractory to the combination of treatment of the underlying disease, intermittent pleural drainage, and dietary control measures, we suggest thoracic duct ligation rather than pleurodesis alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Thoracic duct ligation may be combined with pleurodesis, although the additional benefit of pleurodesis in this setting is not known. Alternative choices include chemical pleurodesis, somatostatin or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      treatment, or thoracic duct embolization under lymphangiogram guidance, if locally available. (See",
"      <a class=\"local\" href=\"#H1067435\">",
"       'Nontraumatic chylothorax'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067400\">",
"       'Pleurodesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067407\">",
"       'Thoracic duct ligation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the majority of patients with traumatic chylothorax (eg, nonsurgical or postoperative), we suggest initial conservative management rather than surgical intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Conservative management includes chest tube drainage and either bowel rest with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      or a high protein-reduced fat diet with MCT supplementation. Close attention to fluid and electrolyte management, nutrition, and the daily volume of pleural drainage is needed. (See",
"      <a class=\"local\" href=\"#H1067386\">",
"       'Dietary control measures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067379\">",
"       'Pleural drainage to control symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88586908\">",
"       'Nonsurgical traumatic chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a chylothorax in a postpneumonectomy space and mediastinal shift to the side of the pneumonectomy, we suggest dietary control measures",
"      <strong>",
"       without",
"      </strong>",
"      chest tube drainage (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Shift of the mediastinum back to the midline suggests development of tension chylothorax, which requires urgent placement of a chest tube, followed by surgery to gain control of the lymphatic leak. (See",
"      <a class=\"local\" href=\"#H175735402\">",
"       'Postpneumonectomy chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a traumatic chylothorax (eg, nonsurgical or postoperative) chylothorax and large volume drainage of chylous fluid (&gt;1L per day) through the chest tube who can tolerate surgery, we recommend early thoracic duct ligation (eg, within 5 to 7 days) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Pleurodesis may be performed at the time of thoracic duct ligation via mechanical abrasion or insufflation of talc. (See",
"      <a class=\"local\" href=\"#H1067400\">",
"       'Pleurodesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067407\">",
"       'Thoracic duct ligation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88586908\">",
"       'Nonsurgical traumatic chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a traumatic chylothorax (eg, nonsurgical or postoperative) and continued pleural drainage after 14 days of conservative therapy, we recommend thoracic duct ligation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A longer duration of conservative therapy is associated with nutritional depletion and high mortality rates. Pleurodesis may be performed at the time of thoracic duct ligation via mechanical abrasion or insufflation of talc. Alternatively, for patients who are not good surgical candidates, chemical pleurodesis via the chest tube is an option. (See",
"      <a class=\"local\" href=\"#H1067407\">",
"       'Thoracic duct ligation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067400\">",
"       'Pleurodesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88586908\">",
"       'Nonsurgical traumatic chylothorax'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1067463\">",
"       'Postoperative (surgical) chylothorax'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapies, such as",
"      <span class=\"nowrap\">",
"       somatostatin/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"        octreotide",
"       </a>",
"       ,",
"      </span>",
"      pleurovenous and pleuroperitoneal shunting, and thoracic duct embolization, have been used in small numbers of patients and are typically employed when the therapies described above have been unsuccessful. (See",
"      <a class=\"local\" href=\"#H7911741\">",
"       'Infrequently used therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/1\">",
"      Maldonado F, Hawkins FJ, Daniels CE, et al. Pleural fluid characteristics of chylothorax. Mayo Clin Proc 2009; 84:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/2\">",
"      Wasmuth-Pietzuch A, Hansmann M, Bartmann P, Heep A. Congenital chylothorax: lymphopenia and high risk of neonatal infections. Acta Paediatr 2004; 93:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/3\">",
"      Orange JS, Geha RS, Bonilla FA. Acute chylothorax in children: selective retention of memory T cells and natural killer cells. J Pediatr 2003; 143:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/4\">",
"      DUMONT AE, MAYER DJ, MULHOLLAND JH. THE SUPPRESSION OF IMMUNOLOGIC ACTIVITY BY DIVERSION OF THORACIC DUCT LYMPH. Ann Surg 1964; 160:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/5\">",
"      Franksson C, Lundgren G, Magnusson G, Ringd&eacute;n O. Drainage of thoracic duct lymph in renal transplant patients. Transplantation 1976; 21:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/6\">",
"      Merrigan BA, Winter DC, O'Sullivan GC. Chylothorax. Br J Surg 1997; 84:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/7\">",
"      Browse NL, Allen DR, Wilson NM. Management of chylothorax. Br J Surg 1997; 84:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/8\">",
"      Jensen GL, Mascioli EA, Meyer LP, et al. Dietary modification of chyle composition in chylothorax. Gastroenterology 1989; 97:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/9\">",
"      Densupsoontorn NS, Jirapinyo P, Wongarn R, et al. Management of chylothorax and chylopericardium in pediatric patients: experiences at Siriraj Hospital, Bangkok. Asia Pac J Clin Nutr 2005; 14:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/10\">",
"      Machado JD, Suen VM, Marchini JS. Is oral nutritional therapy effective for the treatment of chylothorax? A case report. Nutrition 2008; 24:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/11\">",
"      Beghetti M, La Scala G, Belli D, et al. Etiology and management of pediatric chylothorax. J Pediatr 2000; 136:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/12\">",
"      Fern&aacute;ndez Alvarez JR, Kalache KD, Gra��el EL. Management of spontaneous congenital chylothorax: oral medium-chain triglycerides versus total parenteral nutrition. Am J Perinatol 1999; 16:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/13\">",
"      Epaud R, Dubern B, Larroquet M, et al. Therapeutic strategies for idiopathic chylothorax. J Pediatr Surg 2008; 43:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/14\">",
"      Chan EH, Russell JL, Williams WG, et al. Postoperative chylothorax after cardiothoracic surgery in children. Ann Thorac Surg 2005; 80:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/15\">",
"      Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg 1993; 106:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/16\">",
"      Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/17\">",
"      Graham DD, McGahren ED, Tribble CG, et al. Use of video-assisted thoracic surgery in the treatment of chylothorax. Ann Thorac Surg 1994; 57:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/18\">",
"      Maldonado F, Cartin-Ceba R, Hawkins FJ, Ryu JH. Medical and surgical management of chylothorax and associated outcomes. Am J Med Sci 2010; 339:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/19\">",
"      Mares DC, Mathur PN. Medical thoracoscopic talc pleurodesis for chylothorax due to lymphoma: a case series. Chest 1998; 114:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/20\">",
"      Paul S, Altorki NK, Port JL, et al. Surgical management of chylothorax. Thorac Cardiovasc Surg 2009; 57:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/21\">",
"      Griffo S, De Luca G, Stassano P. Chylothorax after abdominal surgery. Gen Thorac Cardiovasc Surg 2010; 58:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/22\">",
"      McGrath EE, Blades Z, Anderson PB. Chylothorax: aetiology, diagnosis and therapeutic options. Respir Med 2010; 104:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/23\">",
"      Fahimi H, Casselman FP, Mariani MA, et al. Current management of postoperative chylothorax. Ann Thorac Surg 2001; 71:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/24\">",
"      Shimizu K, Yoshida J, Nishimura M, et al. Treatment strategy for chylothorax after pulmonary resection and lymph node dissection for lung cancer. J Thorac Cardiovasc Surg 2002; 124:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/25\">",
"      Zabeck H, Muley T, Dienemann H, Hoffmann H. Management of chylothorax in adults: when is surgery indicated? Thorac Cardiovasc Surg 2011; 59:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/26\">",
"      Le Pimpec-Barthes F, D'Attellis N, Dujon A, et al. Chylothorax complicating pulmonary resection. Ann Thorac Surg 2002; 73:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/27\">",
"      Huggins JT. Chylothorax and cholesterol pleural effusion. Semin Respir Crit Care Med 2010; 31:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/28\">",
"      Nair SK, Petko M, Hayward MP. Aetiology and management of chylothorax in adults. Eur J Cardiothorac Surg 2007; 32:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/29\">",
"      Wurnig PN, Hollaus PH, Ohtsuka T, et al. Thoracoscopic direct clipping of the thoracic duct for chylopericardium and chylothorax. Ann Thorac Surg 2000; 70:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/30\">",
"      Kos S, Haueisen H, Lachmund U, Roeren T. Lymphangiography: forgotten tool or rising star in the diagnosis and therapy of postoperative lymphatic vessel leakage. Cardiovasc Intervent Radiol 2007; 30:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/31\">",
"      Alejandre-Lafont E, Krompiec C, Rau WS, Krombach GA. Effectiveness of therapeutic lymphography on lymphatic leakage. Acta Radiol 2011; 52:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/32\">",
"      Hayden JD, Sue-Ling HM, Sarela AI, Dexter SP. Minimally invasive management of chylous fistula after esophagectomy. Dis Esophagus 2007; 20:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/33\">",
"      Kalomenidis I. Octreotide and chylothorax. Curr Opin Pulm Med 2006; 12:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/34\">",
"      Al-Zubairy SA, Al-Jazairi AS. Octreotide as a therapeutic option for management of chylothorax. Ann Pharmacother 2003; 37:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/35\">",
"      Kelly RF, Shumway SJ. Conservative management of postoperative chylothorax using somatostatin. Ann Thorac Surg 2000; 69:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/36\">",
"      Markham KM, Glover JL, Welsh RJ, et al. Octreotide in the treatment of thoracic duct injuries. Am Surg 2000; 66:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/37\">",
"      Demos NJ, Kozel J, Scerbo JE. Somatostatin in the treatment of chylothorax. Chest 2001; 119:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/38\">",
"      Evans J, Clark MF, Mincher L, Varney VA. Chylous effusions complicating lymphoma: a serious event with octreotide as a treatment option. Hematol Oncol 2003; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/39\">",
"      Mohseni-Bod H, Macrae D, Slavik Z. Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: is it safe? Pediatr Crit Care Med 2004; 5:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/40\">",
"      Mincher L, Evans J, Jenner MW, Varney VA. The successful treatment of chylous effusions in malignant disease with octreotide. Clin Oncol (R Coll Radiol) 2005; 17:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/41\">",
"      Paget-Brown A, Kattwinkel J, Rodgers BM, Michalsky MP. The use of octreotide to treat congenital chylothorax. J Pediatr Surg 2006; 41:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/42\">",
"      Roehr CC, Jung A, Proquitt&eacute; H, et al. Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med 2006; 32:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/43\">",
"      Hillerdal G. Yellow nail syndrome: treatment with octreotide. Clin Respir J 2007; 1:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/44\">",
"      Tanaka E, Matsumoto K, Shindo T, Taguchi Y. Implantation of a pleurovenous shunt for massive chylothorax in a patient with yellow nail syndrome. Thorax 2005; 60:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/45\">",
"      Gupta D, Ross K, Piacentino V 3rd, et al. Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax. Ann Thorac Surg 2004; 78:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/46\">",
"      Fremont RD, Milstone AP, Light RW, Ninan M. Chylothoraces after lung transplantation for lymphangioleiomyomatosis: review of the literature and utilization of a pleurovenous shunt. J Heart Lung Transplant 2007; 26:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/47\">",
"      Artemiou O, Marta GM, Klepetko W, et al. Pleurovenous shunting in the treatment of nonmalignant pleural effusion. Ann Thorac Surg 2003; 76:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/48\">",
"      Cope C. Management of chylothorax via percutaneous embolization. Curr Opin Pulm Med 2004; 10:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/49\">",
"      Cope C, Salem R, Kaiser LR. Management of chylothorax by percutaneous catheterization and embolization of the thoracic duct: prospective trial. J Vasc Interv Radiol 1999; 10:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/50\">",
"      Hoffer EK, Bloch RD, Mulligan MS, et al. Treatment of chylothorax: percutaneous catheterization and embolization of the thoracic duct. AJR Am J Roentgenol 2001; 176:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/51\">",
"      Cope C, Kaiser LR. Management of unremitting chylothorax by percutaneous embolization and blockage of retroperitoneal lymphatic vessels in 42 patients. J Vasc Interv Radiol 2002; 13:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/52\">",
"      Boffa DJ, Sands MJ, Rice TW, et al. A critical evaluation of a percutaneous diagnostic and treatment strategy for chylothorax after thoracic surgery. Eur J Cardiothorac Surg 2008; 33:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/53\">",
"      Marcon F, Irani K, Aquino T, et al. Percutaneous treatment of thoracic duct injuries. Surg Endosc 2011; 25:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/54\">",
"      Itkin M, Kucharczuk JC, Kwak A, et al. Nonoperative thoracic duct embolization for traumatic thoracic duct leak: experience in 109 patients. J Thorac Cardiovasc Surg 2010; 139:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/55\">",
"      Agrawal V, Sahn SA. Lipid pleural effusions. Am J Med Sci 2008; 335:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/56\">",
"      Jarman PR, Whyte MK, Sabroe I, Hughes JM. Sarcoidosis presenting with chylothorax. Thorax 1995; 50:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/57\">",
"      Roy, PH, Carr, DT, Payne, WS. The problem of chylothorax. Mayo Clin Proc 1967; 42:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/58\">",
"      O'Callaghan AM, Mead GM. Chylothorax in lymphoma: mechanisms and management. Ann Oncol 1995; 6:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/59\">",
"      Iqbal MH, Smith PR, Bande S. Chylothorax due to angioimmunoblastic T-cell lymphoma. Intern Med J 2009; 39:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/60\">",
"      Ferguson MK. Thoracoscopy for empyema, bronchopleural fistula, and chylothorax. Ann Thorac Surg 1993; 56:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/61\">",
"      Mart&iacute;nez Brocca MA, Garc&iacute;a Garc&iacute;a-Doncel L, Pereira Cunill JL, et al. [Nutritional support in chylothorax secondary to lymphoma]. Nutr Hosp 2002; 17:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/62\">",
"      Asuquo BJ, Gould GA. Recurrent chylothorax in a patient with non-Hodgkins lymphoma: case report. East Afr Med J 2004; 81:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/63\">",
"      Milsom JW, Kron IL, Rheuban KS, Rodgers BM. Chylothorax: an assessment of current surgical management. J Thorac Cardiovasc Surg 1985; 89:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/64\">",
"      Jimenez CA, Mhatre AD, Martinez CH, et al. Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer. Chest 2007; 132:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/65\">",
"      Marts BC, Naunheim KS, Fiore AC, Pennington DG. Conservative versus surgical management of chylothorax. Am J Surg 1992; 164:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/66\">",
"      Sudduth CD, Sahn SA. Pleurodesis for nonmalignant pleural effusions. Recommendations. Chest 1992; 102:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/67\">",
"      Ferguson MK, Little AG, Skinner DB. Current concepts in the management of postoperative chylothorax. Ann Thorac Surg 1985; 40:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/68\">",
"      Patterson GA, Todd TR, Delarue NC, et al. Supradiaphragmatic ligation of the thoracic duct in intractable chylous fistula. Ann Thorac Surg 1981; 32:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/69\">",
"      Rubin JW, Moore HV, Ellison RG. Chylothorax: therapeutic alternatives. Am Surg 1977; 43:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/70\">",
"      Zoetmulder F, Rutgers E, Baas P. Thoracoscopic ligation of a thoracic duct leakage. Chest 1994; 106:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/71\">",
"      Terzi A, Furlan G, Magnanelli G, et al. Chylothorax after pleuro-pulmonary surgery: a rare but unavoidable complication. Thorac Cardiovasc Surg 1994; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/72\">",
"      Shimizu K, Otani Y, Ibe T, et al. Late-onset chylothorax after pulmonary resection and systematic mediastinal lymph node dissection for lung cancer. Jpn J Thorac Cardiovasc Surg 2005; 53:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/73\">",
"      Cerfolio RJ. Chylothorax after esophagogastrectomy. Thorac Surg Clin 2006; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/74\">",
"      Cerfolio RJ, Allen MS, Deschamps C, et al. Postoperative chylothorax. J Thorac Cardiovasc Surg 1996; 112:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/75\">",
"      Lagarde SM, Omloo JM, de Jong K, et al. Incidence and management of chyle leakage after esophagectomy. Ann Thorac Surg 2005; 80:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/76\">",
"      Orringer MB, Bluett M, Deeb GM. Aggressive treatment of chylothorax complicating transhiatal esophagectomy without thoracotomy. Surgery 1988; 104:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/77\">",
"      Sarsam MA, Rahman AN, Deiraniya AK. Postpneumonectomy chylothorax. Ann Thorac Surg 1994; 57:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31241/abstract/78\">",
"      Shirai T, Amano J, Takabe K. Thoracoscopic diagnosis and treatment of chylothorax after pneumonectomy. Ann Thorac Surg 1991; 52:306.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16356 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31241=[""].join("\n");
var outline_f30_32_31241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1069952\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1066254\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1067364\">",
"      THERAPEUTIC OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067371\">",
"      Treatment of the underlying condition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067379\">",
"      Pleural drainage to control symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067386\">",
"      Dietary control measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067400\">",
"      Pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067407\">",
"      Thoracic duct ligation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7911741\">",
"      Infrequently used therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17078932\">",
"      - Somatostatin and octreotide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1067414\">",
"      - Pleuroperitoneal or pleurovenous shunt",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1067421\">",
"      - Thoracic duct embolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1067428\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1067435\">",
"      Nontraumatic chylothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1067442\">",
"      - Malignant chylothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1067449\">",
"      - Idiopathic and benign chylothorax",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175735500\">",
"      Traumatic chylothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1067463\">",
"      - Postoperative (surgical) chylothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175735402\">",
"      - Postpneumonectomy chylothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88586908\">",
"      - Nonsurgical traumatic chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1069952\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/16356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/16356|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/27/33212\" title=\"table 1\">",
"      Causes of chylothorax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36232?source=related_link\">",
"      Chemical pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/10/168?source=related_link\">",
"      Chylous, bloody, and pancreatic ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/45/31448?source=related_link\">",
"      Clinical presentation, diagnosis and management of cholesterol effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37192?source=related_link\">",
"      Etiology, clinical presentation, and diagnosis of chylothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=related_link\">",
"      Mechanisms of pleural liquid accumulation in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=related_link\">",
"      Nutritional support in advanced lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4567?source=related_link\">",
"      Physiology of somatostatin and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30615?source=related_link\">",
"      Talc pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32103?source=related_link\">",
"      The pleura in lung transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31242="The development of immune cells in the fetus and neonate";
var content_f30_32_31242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The development of immune cells in the fetus and neonate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31242/contributors\">",
"     Akhil Maheshwari, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31242/contributors\">",
"     Darlene A Calhoun, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31242/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31242/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31242/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?30/32/31242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?30/32/31242/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?30/32/31242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review will address the development of the different cells of the immune system in fetal and neonatal life and review what is known about how these cells differ in function from adult cells. More general descriptions relating to the development of these cells are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical consequences of the altered functioning of the neonatal immune system, specifically in relation to infections and laboratory testing, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/12/16585?source=see_link\">",
"     \"Immunity of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     T CELLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     T cell development",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thymus arises from the third branchial arch at about six weeks of gestation, with the cortex arising from its ectodermal layer and the medulla from the endoderm. Lymphoid cells migrate over the next two to three weeks, initially from the yolk sac and fetal liver, and then from the bone marrow to colonize the fetal thymus [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These prothymocytes interact with the stroma, proliferate actively, and are triggered to differentiate with expression of the first T cell-specific surface molecules (eg, CD2 and later, CD4 and CD8) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/3\">",
"     3",
"    </a>",
"    ]. A clear delineation of the thymic cortical and medullary regions occurs at 12 weeks of gestation; Hassall's corpuscles appear shortly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/4\">",
"     4",
"    </a>",
"    ]. The most immature thymocytes are found in the subcapsular cortical region, and cells move into the deeper layers as they mature [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early prothymocytes do not express CD3, the T cell receptor (TCR), CD4, or CD8 and are often referred to as \"",
"    <strong>",
"     triple-negative",
"    </strong>",
"    thymocytes\" [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/6\">",
"     6",
"    </a>",
"    ]. The progeny continue to divide and rearrange their TCR genes, and since these cells express both CD4 and CD8, they are now called \"",
"    <strong>",
"     double-positive",
"    </strong>",
"    \" cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. They undergo positive selection by self-major histocompatibility complex (MHC) restriction. More than 95 percent (nearly 50 million) of the cells die each day during this stage [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Negative selection, which occurs next, is mediated by the bone marrow-derived antigen-presenting cells (APC) (eg, dendritic cells and macrophages), which eliminate autoreactive cells either by clonal deletion or clonal anergy (",
"    <a class=\"graphic graphic_figure graphicRef72612 \" href=\"UTD.htm?28/58/29613\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As these thymocytes mature and reach the medulla, they express only one of the CD4 or CD8 antigens. These &ldquo;",
"    <strong>",
"     single-positive",
"    </strong>",
"    &rdquo; T cells then migrate from the thymus to the peripheral lymphoid organs at about 14 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/10\">",
"     10",
"    </a>",
"    ]. By 15 weeks, human thymocytes express a complete set of TCRs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During fetal life, the thymus is the largest lymphoid tissue in terms of body proportions. At birth, it is about two-thirds of its mature weight and reaches its peak mass at around 10 years of age. Subsequently, it continues to involute and is replaced by adipose tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     TCR repertoire",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TCR is composed of two distinct functional subunits, each specialized for a different function [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/12\">",
"     12",
"    </a>",
"    ]. The first, highly polymorphic subunit is structured uniquely for each T cell for antigen recognition; it is composed of two polypeptide chains, alpha and beta (except in a specific T cell subset where it consists of gamma and delta chains) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The second subunit, known as CD3, is a trimolecular complex, and is involved in signal transduction and cellular activation (",
"    <a class=\"graphic graphic_figure graphicRef65506 \" href=\"UTD.htm?29/42/30369\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extracellular region of the TCR resembles an immunoglobulin (Ig) Fab fragment, and derives its structural diversity from recombinatorial permutations involving a set each of Variable (V), Diversity (D), and Joining (J) gene segments (",
"    <a class=\"graphic graphic_figure graphicRef68530 \" href=\"UTD.htm?40/10/41135\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The variable domain is situated in the N-terminal end of the",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    (or",
"    <span class=\"nowrap\">",
"     gamma/delta)",
"    </span>",
"    chains, whereas the C terminal end is the constant region [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/12\">",
"     12",
"    </a>",
"    ]. The variable domains consist of V, D, and J elements in the beta chain, and V and J in the alpha chain [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/16\">",
"     16",
"    </a>",
"    ]. Antigen-binding sites are formed by three \"complementarity-determining regions\" (CDRs). CDR3, the most extensive of these subunits, serves as a key site for antigen recognition [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By mid-gestation, all of the TCR Vbeta families (V here refers to the variable domain of the beta chain, and should be recognized as different from the V gene segments mentioned previously) are expressed, but they have shorter CDR3 regions. This is primarily due to limited expression of the enzyme terminal deoxynucleotidyl transferase (Tdt), which induces N-terminal diversity, and consequently, CDR3 heterogeneity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/18\">",
"     18",
"    </a>",
"    ]. In term infants, the T cell Vbeta repertoire is similar to that seen in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. Cord blood T cells from term infants are also able to expand the TCR beta repertoire following stimulation with bacterial toxins [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=see_link\">",
"     \"T cell receptor genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Circulating T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total lymphocyte count and the total T cell numbers are markedly increased in cord blood and peripheral blood for the first several months of life. Cord lymphocytes average 5400",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    and CD3 cells average 3100",
"    <span class=\"nowrap\">",
"     cells/uL;",
"    </span>",
"    thus a total lymphocyte count less than 2500",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    or a total T cell count (CD3) less than 1500",
"    <span class=\"nowrap\">",
"     cells/uL",
"    </span>",
"    suggests a T cell deficiency. T cell subpopulations gradually increase in number beyond 19 weeks gestation, and continue to rise after birth, peaking at about six to nine months of age. Subsequently, the numbers decline to adult levels by six to seven years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In full-term neonates, CD4+ cells constitute a higher proportion of T cells than in adults. In contrast, there are fewer CD8+ cells both in terms of absolute numbers and as a percentage of total T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/23\">",
"     23",
"    </a>",
"    ]. Consequently, the",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio is as high as 4.9:1 during the perinatal period, declining to adult values of approximately 2:1 by four years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Preterm infants have higher numbers of CD4+ T cells, but the number of CD8+ T cells do not seem to change with gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These numbers decrease with perinatal stress, but normalize by three weeks of age except in some very-low-birth-weight infants [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peripheral T cells in the fetus and neonate are in a relatively immature transitional state; in cord blood, nearly 85 percent of T cells express CD38 (compared with less than 5 percent of adult cells), but lack other markers of activation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/26\">",
"     26",
"    </a>",
"    ]. Cord blood T cells differ also in being predominantly naive (80 to 90 percent express the CD45RA phenotype, compared with 40 to 60 percent of the adult cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The percentage of memory T cells (CD45RO) increases in healthy infants during the first few years of life, but reaches adult levels only by the second decade [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/27\">",
"     27",
"    </a>",
"    ]. Neonatal T cells also have lower expression of CDw29 and CD11b, providing further evidence to a lack of previous stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. In addition, these cells show increased susceptibility to apoptosis indicating high cell turn-over. Elevated CD3 levels reflect increased output of T cells from the thymus gland, and can be readily assessed by analyzing the numbers of T cell receptor excision circles (TRECs) in cord or neonatal blood [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/28\">",
"     28",
"    </a>",
"    ]. Very low or absent TRECs in newborn blood, as determined by PCR, are used as a screening test for severe combined immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link&amp;anchor=H6#H6\">",
"     \"Severe combined immunodeficiency (SCID): An overview\", section on 'Newborn screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     T cell function",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Proliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord blood T cells from premature infants have significantly lower mitogen-induced proliferation responses than those from term infants and adults, which are comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Similarly, proliferative responses to monoclonal antibodies of T cell markers (eg, CD3, CD2) are dramatically less than adult lymphocytes, and resemble adult naive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These responses improve as the number of peripheral blood memory T cells increase. When tested with allogeneic cells (mixed lymphocyte reaction), however, cord blood lymphocytes respond better, although still somewhat less than cells from adult subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/27,32-35\">",
"     27,32-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cytokine production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal concentrations of proinflammatory cytokines, such as interleukin-1 (IL-1), IL-6, tumor necrosis factor alpha (TNF-alpha), interferon alpha (IFN-alpha), and IFN-beta, are comparable to adults, and increase in a similar manner during sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Premature infants, however, produce lower amounts of TNF-alpha and IFN-alpha as compared with those infants born at term. Among the cytokines involved in adaptive immunity, only IL-2 concentrations are comparable; others like IL-5, IL-10, and IL-15, are significantly lower than those in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/39-42\">",
"     39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transforming growth factor (TGF)-beta1 and macrophage inflammatory protein-1alpha (MIP)-1alpha, both of which play a negative role in hematopoiesis, are present in much lower concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/43\">",
"     43",
"    </a>",
"    ]. The concentrations of hematopoietic colony stimulating factors, including IL-3, Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), G-CSF and Monocyte-CSF (M-CSF), are slightly lower as compared to adults, but even full-term infants are unable to mount adequate responses during stress [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newborn CD4+ T cells produce lower levels of IFN-gamma in vitro than adult naive T cells. In contrast, neonatal and adult CD8+ T cells produce similar levels of IFN-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most deficiencies associated with cytokines are caused by altered post-transcriptional mRNA regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/47\">",
"     47",
"    </a>",
"    ]. It is believed that lower concentrations of some of these cytokines are caused by a relative paucity of memory or primed T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/48\">",
"     48",
"    </a>",
"    ]. However, genetic and other individual traits, such as atopy, are also likely to be important determinants of the cytokine response [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD8+ T cells proliferate and differentiate into cytotoxic T cells upon antigen presentation and activation, while naive CD4+ T cells differentiate into distinct effector T-helper (Th) subsets. These differentiated T cells were originally categorically designated Th1 and Th2 cells based on distinct functional properties [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/52\">",
"     52",
"    </a>",
"    ]. Th1-derived cytokines, such as IFN-gamma and IL-2 play a key role in initiating early resistance to pathogens, and induction of cell-mediated immunity. Th2 cytokines, such as IL-4, IL-5, IL-9, and IL-13, drive the system toward immune tolerance rather than toward defense from microbial infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .) Accumulating evidence suggests that Th1 responses in newborns are compromised at several steps including deficient production of Th1 type cytokines by neonatal CD4+ T cells and hyporesponsiveness of neonatal macrophages to stimulation by IFN-gamma. These deficiencies contribute to the apparently weak cellular immunity in newborns biased towards a Th2 type response [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the original Th1 and Th2 description, a distinct differentiated T-cell population, Th17 cells, has been shown to have a pathogenic role in allergic, autoimmune and other chronic inflammatory diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Th17 cells play a protective role in immunity to infection, where they take on Th1-like effector functions to promote pathogen clearance by enhancing neutrophil recruitment to sites of infection and activating macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/55,56,58\">",
"     55,56,58",
"    </a>",
"    ]. While the role of Th17 cells early in life remains unclear, cord blood mononuclear cells appear to have a limited capacity to produce IL-17 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Antigen-specific responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response of T cells to specific antigens can be assessed in terms of proliferation or cytokine production. These responses usually require previous exposure to the corresponding antigen, and are generally not detected at birth or from cord blood unless there was an intrauterine exposure. Neonatal T cells do, however, respond well to certain antigens, such as",
"    <span class=\"nowrap\">",
"     tetanus/diphtheria",
"    </span>",
"    toxoids, influenza, and mycobacterial antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/35\">",
"     35",
"    </a>",
"    ]. In response to superantigens, cord blood T cells produce lesser amounts of IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/59\">",
"     59",
"    </a>",
"    ]. After stimulation, the percentage of Vbeta2+T cells (which determine potential reactivity to superantigens) and the number of memory T cells increase significantly, similarly as that observed in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, unlike adult T cells, cord blood T cells are unable to respond when restimulated with the same superantigen. This tolerance induction in cord blood T cells may be due to the underlying immunologic naivete [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/59,61\">",
"     59,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other T cell subgroups",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cytotoxic T-lymphocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic T-lymphocytes (CTLs) are important in host defense against intracellular infections, in allograft rejection, and tumor cell surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/47,62\">",
"     47,62",
"    </a>",
"    ]. CTLs use two well-established mechanisms for cell lysis, one involving release of extracellular mediators (such as the pore-forming",
"    <span class=\"nowrap\">",
"     perforin/granzyme",
"    </span>",
"    system), and a second",
"    <span class=\"nowrap\">",
"     Fas/Fas",
"    </span>",
"    ligand dependent pathway that leads to target cell apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CTL cytotoxicity is evident by 18 weeks of gestation, but is far less efficient than adult cells even at term (&lt;20 percent of adult CTL activity) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/65\">",
"     65",
"    </a>",
"    ]. Perforin expression in neonatal CTLs is about 30 percent of adult levels [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/48\">",
"     48",
"    </a>",
"    ]. CD28, which is a T cell activation marker, is also expressed to significantly lower levels than in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/34\">",
"     34",
"    </a>",
"    ]. Similar results are observed when other assays are used; neonatal cells showed only 33 percent of",
"    <span class=\"nowrap\">",
"     lectin/mitogen-dependent",
"    </span>",
"    cytotoxicity of adult cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/66\">",
"     66",
"    </a>",
"    ]. Circulating inhibitors, such as alpha-fetoprotein and prostaglandins, might also lead to lower CTL activity in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gamma delta T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma delta T cells represent a distinct functional subset, with the majority lacking surface expression of both CD4 and CD8 (",
"    <a class=\"graphic graphic_figure graphicRef55339 \" href=\"UTD.htm?8/4/8257\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. These cells are detectable in the fetal thymus and liver at six to eight weeks of gestation, and comprise nearly 10 percent of the peripheral blood T cells at 16 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Subsequently, the numbers decline gradually to reach about 3 percent at term [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gamma delta T cells are present mainly on skin and mucosal surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/68\">",
"     68",
"    </a>",
"    ]. The exact functions of these T cells are not well-understood, although these cells are activated and proliferate in response to non-peptide metabolic compounds produced by various microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Gamma delta T cells can lyse target cells with the",
"    <span class=\"nowrap\">",
"     perforin/granzyme",
"    </span>",
"    system, similar to cytotoxic T cells, and can secrete cytokines like IFN-gamma and TNF-alpha upon activation. The cytotoxicity of neonatal gamma delta T cells is significantly less than that of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal gamma delta T cells have a more diverse repertoire, but a more limited junctional diversity compared with those found in adults. This diversity is retained throughout the first year of life, and then decreases gradually over the first decade [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/71\">",
"     71",
"    </a>",
"    ]. Overall, however, gamma delta T cells have a relatively restricted repertoire in comparison to the alpha beta T or B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Regulatory T cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-regulatory cells (Tregs) downregulate T-cell responses to both foreign and self antigens, thereby playing an important role in balancing",
"    <span class=\"nowrap\">",
"     Th1/Th2",
"    </span>",
"    effector lineages [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Treg cells, including both natural CD4+ CD25+ Tregs as well as IL-10-producing Tregs, express the",
"    <span class=\"nowrap\">",
"     forkhead/winged-helix",
"    </span>",
"    family transcriptional repressor-p3 (Foxp3) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/75\">",
"     75",
"    </a>",
"    ], a commonly used but not entirely specific marker for Tregs [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/76\">",
"     76",
"    </a>",
"    ]. Knowledge about Treg function early in life is limited, although Tregs have been detected in cord blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     B CELLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     B cell development",
"    </span>",
"    &nbsp;&mdash;&nbsp;B cell progenitors, pro-B cells, are derived from pluripotent hematopoietic cells in the bone marrow (",
"    <a class=\"graphic graphic_figure graphicRef55339 \" href=\"UTD.htm?8/4/8257\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The first recognizable B cell progenitor, the large pre-B cell, is characterized by the presence of cytoplasmic &micro; heavy chains [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/79\">",
"     79",
"    </a>",
"    ]. Immature B cells undergo a selection process analogous to T cells to eliminate self-identifying clones (clonal selection and deletion), although other mechanisms may maintain self-tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Once B cells begin to express surface IgM (sIgM), they are ready to leave the bone marrow and enter the peripheral circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pre-B cells can be identified in the fetal liver as early as seven weeks of gestation, and in the marrow by 12 weeks. sIgM+ B cells are found in the fetal liver by nine weeks and in the bone marrow, peripheral blood, and spleen by 12 weeks. B cells with sIgA, sIgG, and sIgD isotypes appear between 10 and 12 weeks. There is also increased traffic to the lymphoid tissues, and by 22 weeks, the proportion of B cells in the spleen, peripheral blood, and bone marrow is similar to that in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. By 30 weeks, there are no detectable pre-B cells in the fetal liver, and the bone marrow becomes the exclusive site for B cell maturation. Plasma cells are not generally found until 20 weeks gestation.",
"    <span class=\"nowrap\">",
"     IgM/IgD+",
"    </span>",
"    B cells populate the lymph nodes by 16 to 17 weeks gestation and the spleen by 16 to 21 weeks. In fetal lymph nodes, primary nodules develop around the follicular dendritic cells by 17 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Immunoglobulin repertoire",
"    </span>",
"    &nbsp;&mdash;&nbsp;Receptor diversity in the antigen binding site originates from DNA recombination involving various V, D, or J gene segments, giving rise to a large number of V(D)J permutations (",
"    <a class=\"graphic graphic_figure graphicRef68530 \" href=\"UTD.htm?40/10/41135\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/86\">",
"     86",
"    </a>",
"    ]. Additional receptor diversity is generated by imprecise gene segment joins, additional nucleotides added to the splice junction of the VDJ joined by the enzyme terminal deoxynucleotidyl transferase (TdT), and somatic mutations (for B cells only, not T cells). Thereafter, these VDJ or VJ (light chains) units join to their respective constant region gene segments [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the fetus and neonate, the Ig repertoire is relatively restricted. During early and mid-gestation, certain heavy chain V gene segments are preferentially expressed. Early in fetal life, the JH proximal VH gene segments are utilized preferentially, and consequently, the CDR3 region of the rearranged VDJ gene segment is shorter than that in adults. This leads to relatively limited junctional diversity, but the altered architecture of the antigen-binding site might allow greater polyspecificity of antigen binding (at a cost of lower antibody affinity) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utilization of VH gene families spreads out more evenly with increasing gestation. However, even at term, cord blood B cells have a higher usage of VH genes of the VH 1 and VH 5 family with decreased VH 3 gene use compared with adult B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/91\">",
"     91",
"    </a>",
"    ]. In general, the antibody response in neonates is of low affinity, and restricted to the IgM isotype. The somatic mutation of the heavy and light Ig variable region genes and the selection of higher affinity antibody-producing B cells is limited at birth and increases very slowly after 10 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Circulating B cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, the proportion of B cells is similar to that in adults, but the absolute number of B cells is significantly higher [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/93\">",
"     93",
"    </a>",
"    ]. The number peaks at about three to four months of age, and declines to adult levels by six to seven years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/94\">",
"     94",
"    </a>",
"    ]. Preterm infants have B cell numbers that are comparable to those in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/95\">",
"     95",
"    </a>",
"    ]. However, the number is smaller in growth-restricted infants [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/95\">",
"     95",
"    </a>",
"    ]. Unlike adults, most B cells in cord blood express activation markers (CD25, CD23, transferrin receptor) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     B cell function",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Immunoglobulin production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetus and neonate are capable of mounting antigen-specific antibody responses, although at a lower intensity than adults. The presence of allergen-specific IgE in cord blood, anti-tetanus IgM in cord blood sera of newborns whose mothers were vaccinated during pregnancy, and reactivity to Ascaris antigens in the event of maternal infestation are but a few examples [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this response remains immature [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/1\">",
"     1",
"    </a>",
"    ]. Infants are incapable of responding to all of the antigens in a vaccine, and often have delayed isotype switch [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/99\">",
"     99",
"    </a>",
"    ]. T cell-dependent antibody responses mature much earlier than T cell-independent B cell (antibody) responses, which remain compromised during infancy, but neonates and infants may require multiple immunizations to achieve or sustain titers comparable to those in older individuals. The interval from birth is a more important determinant of antibody response than the actual gestational age. Both preterm and term infants immunized with diphtheria toxoid at 0 to 10 days of age had poorer responses than similarly immunized adults, but the response was better when vaccination was deferred until one to two months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/99\">",
"     99",
"    </a>",
"    ]. With certain antigens like hepatitis B, however, premature infants may show a relatively poorer early response than their term counterparts, although these deficiencies correct during later infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serum immunoglobulin (Ig) concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum Ig concentrations remain very low until 18 to 20 weeks gestation. Most of the newborn infant's serum immunoglobulins are derived from the active transplacental transfer of maternal IgG (particularly IgG1 and IgG3) during the third trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/101\">",
"     101",
"    </a>",
"    ]. In full-term neonates, serum IgG concentrations are equal to or even higher than maternal serum IgG concentrations, but the concentrations are lower in the preterm neonate, as early delivery results in deprivation of these maternal antibodies. In one study, for example, nearly all infants born before 32 weeks gestation had serum IgG concentrations less than 400",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at birth (compared with term infants who had serum concentrations around 1000",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/102\">",
"     102",
"    </a>",
"    ]. The concentrations decrease after birth (through normal catabolism) to a nadir of 300 to 500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    between three and five months of age, when the infant starts producing increasing amounts of his own. Because of starting at a lower level, this nadir can be much lower, and earlier, in preterm infants. Cord blood Ig levels also tend to be lower in growth-restricted neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum levels of IgA, IgM and IgE are very low even in term infants, since these do not cross the placenta. The normal fetus produces IgM and IgA autoantibodies to many self-antigens, although the host defense role of these antibodies remains unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/104\">",
"     104",
"    </a>",
"    ]. However the fetus is capable of producing appreciable amounts of IgM, when faced with an intrauterine infection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other B cell subgroups",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     B-1 cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;B-1 cells were originally identified as a distinct B-cell subset by the surface expression of CD5, which is a T-cell antigen. To differentiate from the B-cells seen in adults, These CD5+ cells were defined as the \"B-1\" subset, to differentiate them from the B cells seen in adults. B-1 cells distinct from the conventional adult \"B-2\" population by virtue of their earlier appearance in ontogeny, capacity for bone marrow-independent self-renewal, and constitutive expression of signal transducer and activator of transcription-3 (STAT3) (",
"    <a class=\"graphic graphic_figure graphicRef55339 \" href=\"UTD.htm?8/4/8257\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/106\">",
"     106",
"    </a>",
"    ]. B-1 cells express the B-cell-lineage antigens CD19 and CD45R, although CD45R is present at lower levels on B-1 cells than on B-2 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/85,107,108\">",
"     85,107,108",
"    </a>",
"    ]. B-1 cells in the peritoneal and pleural cavities can be identified by their unusual CD11b+ sIgM (hi) sIgD(low) phenotype and can be further subdivided on the basis of differential expression of the cell-surface antigen CD5, into CD5+ CD11b+ sIgM(hi) sIgD(low) B-1a cells and CD5- CD11b+ sIgM(hi) sIgD(low) B-1b cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These cells are the predominant B cell type during fetal life, and have a distinctive anatomic localization in the fetal spleen and the peritoneal cavity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/85,108\">",
"     85,108",
"    </a>",
"    ]. B-1 cells appear in the spleen at 15 weeks, and are seen in the lymph node primary follicles at about 17 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/110\">",
"     110",
"    </a>",
"    ]. In adults, CD5 expression is found on about 25 to 35 percent of total B cells and 1 to 7 percent of all peripheral blood mononuclear cells. In contrast, CD5+ B cells represent approximately 90 percent of the total cord blood B cells. This number decreases to 75 to 80 percent during infancy, and reaches adult levels only by late adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact function of B-1 cells in the fetus is still unclear. The functional characteristics of B-1 cells, such as the unique localization, broad polyspecific specificities, and a restricted Ig repertoire, suggest these cells play a role in innate, rather than adaptive immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/111\">",
"     111",
"    </a>",
"    ]. Follicular B-2 cells respond to protein antigens, and with T-cell help, undergo immunoglobulin heavy chain class-switching and affinity maturation, In contrast, B-1 cells respond mainly to T-cell-independent immunogens that include carbohydrate antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/85,108\">",
"     85,108",
"    </a>",
"    ]. The two types of B-1 cell, B-1a and B-1b, show functional differences during the immune response. B-1a cells spontaneously secrete IgM, which provides a first line of defense against certain encapsulated bacteria, such as Streptococcus pneumoniae, whereas antibody production by B-1b cells is induced and has a role in the ultimate clearance of the pathogen and in providing long-term protection [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/112,113\">",
"     112,113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     T AND B CELL INTERACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell signals are crucial for the proliferation, differentiation, and survival of B cells, and include both antigen presentation and humoral signals (cytokines like IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, and IFN-gamma) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/114\">",
"     114",
"    </a>",
"    ]. Several pairs of other receptor-ligand molecules are also involved, including the CD40-CD40 ligand (CD40L) in B cell immunoglobulin isotype switching, and others like",
"    <span class=\"nowrap\">",
"     B7/CD28,",
"    </span>",
"    CD11a",
"    <span class=\"nowrap\">",
"     (LFA-1)/CD54",
"    </span>",
"    (ICAM-1), and CD58",
"    <span class=\"nowrap\">",
"     (LFA-3)/CD2",
"    </span>",
"    in T- and B cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/114\">",
"     114",
"    </a>",
"    ]. About 30 percent of naive neonatal T cells express CD40L, compared to 80 percent of the naive T cells from adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, once primed with mitogen(s) and IL-2, which converts naive T- cells to the memory phenotype, neonatal T cell CD40L expression is upregulated to adult concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/116\">",
"     116",
"    </a>",
"    ]. The capacity of neonatal B cells to differentiate into plasma cells and undergo isotype switching can be variable, but in general, neonatal T cells are less efficient at providing humoral and CD40-dependent activation signals [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/117\">",
"     117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NATURAL KILLER CELLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     NK cell development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural Killer (NK) cells are large granular lymphocytes that have a cytotoxic function and play an important role in immunity against viruses and in tumor surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/118\">",
"     118",
"    </a>",
"    ]. These cells do not express T cell antigen receptors (TCR), pan T cell marker CD3, or the surface immunoglobulin B cell receptor, but do express CD16 (Fc gamma receptor IIIa, Fc gamma RIIIa) and",
"    <span class=\"nowrap\">",
"     CD56/neural",
"    </span>",
"    cell adhesion molecule in humans, and",
"    <span class=\"nowrap\">",
"     NK1.1/NK1.2",
"    </span>",
"    in certain strains of mice. Up to 80 percent of NK cells also express CD8 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/119\">",
"     119",
"    </a>",
"    ]. NK cells were named \"natural killers\" because of an initial notion that these cells do not require activation to kill cells missing \"self\" markers of major histocompatibility complex (MHC) class I [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/120,121\">",
"     120,121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NK cells can be detected as early as six weeks of gestation, and the number increases progressively until birth. In cord blood, 10 to 15 percent of all lymphocytes are NK cells, which is comparable to the percentage in adult peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/122\">",
"     122",
"    </a>",
"    ]. The phenotype of fetal NK cells, however, is different from that of NK cells in adults. Fifty to 80 percent fetal NK cells express CD3gamma, epsilon, delta, and sigma proteins, unlike a much smaller number in term infants, or in adults where only CD3 sigma is expressed [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/122\">",
"     122",
"    </a>",
"    ]. On the other hand, only 30 to 50 percent of the fetal NK cells express CD16 (compared with more than 90 percent of neonatal and adult NK cells). Similarly, CD56 and CD57 are expressed poorly on fetal or neonatal NK cells, compared to nearly 50 percent positivity in adult NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/122,123\">",
"     122,123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     NK cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;NK cells recognize viral-infected cells and tumor cells by the absence or decreased expression of MHC class I molecules on the cell's surface [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/124,125\">",
"     124,125",
"    </a>",
"    ]. Their MHC-unrestricted killing is mediated by",
"    <span class=\"nowrap\">",
"     perforin/granzyme",
"    </span>",
"    apoptotic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/126\">",
"     126",
"    </a>",
"    ]. The other mechanism of cytolysis is antibody-dependent cell-mediated cytotoxicity (ADCC), where target cell-bound IgG1 or IgG3 triggers the FcgRIIIa receptor on the NK cell [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/125,127\">",
"     125,127",
"    </a>",
"    ]. NK cells are also believed to play a key role in maintaining immunologic tolerance at the maternal-fetal interface [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal NK cells have a significantly lower cytolytic activity (including ADCC) against tumor cell target cell lines than adults, but it increases with gestational age parallel to increasing expression of CD56 and CD16 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/116,122\">",
"     116,122",
"    </a>",
"    ]. However, even at term, the cytolytic activity is only 50 to 80 percent of adult levels [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NK cells should not be confused with the natural killer T cells, a heterogeneous group of T cells that express an alpha beta T cell receptor in addition to some of the NK cell markers. Many of these cells recognize the non-polymorphic CD1d molecule, an antigen-presenting molecule that binds self- and foreign lipids and glycolipids. NK T cells constitute only 0.2 percent of all peripheral blood T cells. These cells play an important role in mucosal immunity and in the pathogenesis of",
"    <span class=\"nowrap\">",
"     inflammatory/allergic",
"    </span>",
"    conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/130\">",
"     130",
"    </a>",
"    ]. Their role during fetal life remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MONOCYTES AND MACROPHAGES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryonic macrophages are first observed in the yolk sac at three to four weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/131\">",
"     131",
"    </a>",
"    ]. Conventionally, macrophages were believed to be progeny of bone marrow-derived monocytes. However, more observations suggest that the macrophage ontogeny in early embryos may be different, arising instead from yolk sac-derived primitive macrophages before the development of adult monocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/132-134\">",
"     132-134",
"    </a>",
"    ]. Later, during the second month, as hematopoiesis is established in the fetal liver and the yolk sac is open to fetal circulation, monocytes are seen in high proportions, and constitute nearly 70 percent of all hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/135\">",
"     135",
"    </a>",
"    ]. Over the next six weeks, as erythroid cells predominate, this proportion falls to 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At five weeks, there are two distinct cell populations with a",
"    <span class=\"nowrap\">",
"     dendritic/macrophage",
"    </span>",
"    structure in the yolk sac, mesenchyme, and the fetal liver. The larger subgroup is MHC II-negative with only a minor population expressing these antigens. MHC II-negative cells appear in the thymic cortex, marginal zones of lymph nodes, splenic red pulp, and in the midst of erythropoietic activity in the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/136\">",
"     136",
"    </a>",
"    ]. A few MHC II-positive cells are seen in the liver at seven to eight weeks of gestation, the lymph nodes at 11 to 13 weeks of gestation, and the T cell areas of the developing thymic medulla by 16 weeks of gestation. Subsequently, the numbers increase gradually, and MHC class II-positive cells can be seen in the skin and gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/136,137\">",
"     136,137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although monocytes and promonocytes are present in the fetal liver, intravascular monocytes are not observed until about the fifth month of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/135\">",
"     135",
"    </a>",
"    ]. Circulating monocytes remain rare until the bone marrow becomes the predominant site of hematopoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/138\">",
"     138",
"    </a>",
"    ]. At 30 weeks, monocytes comprise 3 to 7 percent of hematopoietic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/139\">",
"     139",
"    </a>",
"    ]. Term cord blood studies show a relative monocytosis, which persists during the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/140,141\">",
"     140,141",
"    </a>",
"    ]. The average monocyte count at birth increases linearly in infants born between 22 to 42 weeks gestation, with a slight increase observed during the first two weeks after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/142\">",
"     142",
"    </a>",
"    ]. The reference range at 40 weeks gestation extends from 300 to",
"    <span class=\"nowrap\">",
"     3300/&micro;L",
"    </span>",
"    (mean",
"    <span class=\"nowrap\">",
"     1400/&micro;L).",
"    </span>",
"   </p>",
"   <p>",
"    Information on tissue macrophage kinetics in the neonatal period is mainly from autopsy studies. Histologic examination of lung tissue from stillborn infants, for example, shows only a few macrophages, but the numbers seem to increase rapidly during the early neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/143\">",
"     143",
"    </a>",
"    ]. This increase is caused both by an influx of monocytes from the circulation, and from local proliferation of alveolar macrophages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monocytes and macrophages can be identified using cytochemical techniques that detect cellular constituents, such as nonspecific esterase and peroxidase, or antigenic markers, such as CD11a, CD11b, CD11c, CD14, and the MHC complex, most of which seem to be developmentally regulated [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/144-151\">",
"     144-151",
"    </a>",
"    ]. A lower proportion of cord blood macrophages stain for esterase, although there are no discernible differences in peroxidase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/152-154\">",
"     152-154",
"    </a>",
"    ]. Neonatal monocytes also have lower expression levels of the aforementioned surface markers, except for CD14 [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies on",
"    <span class=\"nowrap\">",
"     monocyte/macrophage",
"    </span>",
"    cell function have been done on cord blood, and fetal cells have not been evaluated to the same extent thus far. Term cord-blood monocytes produce IL-1, IFN-alpha, and TNF-alpha in concentrations that are comparable to those of adults, but the levels of IFN-gamma, IL-8, IL-10, and GM-CSF are lower. These cells also produce lower concentrations of extracellular proteins (such as fibronectin), and bioreactive lipids (such as leukotriene B4) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/156-158\">",
"     156-158",
"    </a>",
"    ]. Impaired monocyte function in neonates may be partially responsible for poorer cytokine responses of neonatal T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/159\">",
"     159",
"    </a>",
"    ] and the diminished delayed-type hypersensitivity (DTH) skin test reactions seen before one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several lines of evidence now indicate that macrophages are dynamic and heterogeneous cells that are polarized into the classically-activated M1 macrophages that express various inflammatory signals, and the described M2 macrophages that display antiinflammatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/161\">",
"     161",
"    </a>",
"    ]. The effect of development on macrophage polarization is not known, although cord blood monocytes (versus monocytes from adults) are relatively unable to mount a robust inflammatory cytokine response [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/162,163\">",
"     162,163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although cord-blood mononuclear cells can phagocytose at a level comparable to that seen in the adult, chemotaxis is reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/164-166\">",
"     164-166",
"    </a>",
"    ]. The ability of fetal and neonatal monocytes to kill a variety of pathogens including S. aureus, S. epidermidis, E. coli, and C. albicans is equivalent to that of adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/144,164\">",
"     144,164",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=see_link\">",
"     \"Antigen presenting cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DENDRITIC CELLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     DC development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dendritic cells (DCs) are a discrete leukocyte population with a highly developed antigen-presenting function [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/145\">",
"     145",
"    </a>",
"    ]. DC populations have been grown from separated hematopoietic precursors, suggesting a common granulocyte-monocyte-dendritic cell progenitor (",
"    <a class=\"graphic graphic_figure graphicRef55339 \" href=\"UTD.htm?8/4/8257\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/146\">",
"     146",
"    </a>",
"    ]. Cells with a",
"    <span class=\"nowrap\">",
"     dendritic/macrophage",
"    </span>",
"    structure are present in the yolk sac, mesenchyme, and the liver at four to six weeks of age. DCs are detectable in the skin by six to seven weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human peripheral blood DCs include mainly two subgroups based on the expression of CD11c [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/161,162\">",
"     161,162",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloid DCs (mDCs) are CD11c+ cells that express myeloid markers, such as CD13, CD33, and CD11b.",
"     </li>",
"     <li>",
"      Plasmacytoid DCs (pDCs) are CD11c- and have a plasmacytoid morphology with well-developed rough endoplasmic reticulum and Golgi apparatus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     DC function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cord blood-DCs represent about 0.3 percent of all mononuclear cells. Most studies show an increased number and proportion of pDCs in cord blood compared with adult peripheral blood, with pDC:mDC ratios of 1-3:1 that contrast with the usual 1:2 ratio in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies of neonatal DCs have been carried out using in vitro monocyte-derived dendritic cells (MDDCs), because of the low frequency of DCs in the peripheral blood. Compared with pDCs from adults, cord blood DCs exhibit low or no basal expression of co-stimulatory molecules CD40, CD80, or CD86, show an impaired maturational response following stimulation with agonists for various toll-like receptors (measured as increase in the expression of co-stimulatory molecules and production of IFN-alpha, TNF-alpha, IL-1, IL-6, and IL-12), and perform poorly at accessory function [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/151,167\">",
"     151,167",
"    </a>",
"    ]. Cord-blood dendritic cells have lower expression levels of ICAM-1 and MHC antigens than in adults. These cells are also poor stimulators of mixed lymphocyte reactions, regardless of whether cord or adult mononuclear or T cells were used as the responders [",
"    <a class=\"abstract\" href=\"UTD.htm?30/32/31242/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of the neonatal immune system have been summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef76122 \" href=\"UTD.htm?1/58/1965\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     NEUTROPHILS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and deficiencies of neutrophils in the neonatal immune system are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/12/16585?source=see_link\">",
"     \"Immunity of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6345244\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The key differences between the neonatal and adult immune systems are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef76122 \" href=\"UTD.htm?1/58/1965\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Early in T cell development, CD3, CD4, and CD8 are not expressed (triple-negative thymocytes). T cell precursors go on to express both CD4 and CD8 (double-positive cells). They then undergo positive selection and then negative selection (",
"      <a class=\"graphic graphic_figure graphicRef72612 \" href=\"UTD.htm?28/58/29613\">",
"       figure 1",
"      </a>",
"      ). As the T cells mature, they express only one of the CD4 or CD8 antigens (single-positive cells). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'T cell development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T cell numbers peak at six to nine months of age and decline to adult levels by six to seven years of age. There is a higher proportion of CD4+ T cells in full-term neonates than in adults. Thus, the",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratios is as high as 4.9:1 during the perinatal period and decline to adult values of approximately 2:1 by four years of age. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Circulating T cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral T cells in the fetus and neonate are in a relatively immature transitional state. Neonatal concentrations of proinflammatory cytokines are comparable to adults, but most cytokines involved in adaptive immunity are lower as are mitogen-induced proliferative responses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'T cell function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The proportion of B cells at birth is similar to that in adults, but the absolute number of B cells is significantly higher. The number peaks at about three to four months of age, and declines to adult levels by six to seven years of age. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Circulating B cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The immunoglobulin repertoire is relatively restricted in the fetus and neonate. The altered architecture of the antigen-binding site may allow greater polyspecificity of antigen binding at the cost of lower antibody affinity. The fetus and neonate are capable of mounting antigen-specific antibody responses, although at a lower intensity than adults. Infants are incapable of responding to all of the antigens in a vaccine, and often have delayed isotype switch. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Immunoglobulin repertoire'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Immunoglobulin production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most of the newborn infant&rsquo;s serum immunoglobulins are derived from the active transplacental transfer of maternal IgG (particularly IgG1 and IgG3) during the third trimester of pregnancy. The concentrations are lower in the preterm neonate, because early delivery results in deprivation of these maternal antibodies. Concentrations decrease after birth (through normal catabolism) to a nadir of 300 to 500",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      between three and five months of age in term neonates, when the infant starts producing increasing amounts of his own. The serum levels of IgA, IgM, and IgE are very low even in term infants, since these do not cross the placenta. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Serum immunoglobulin (Ig) concentrations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal and neonatal natural killer (NK) cells have lower cytolytic activity than adult NK cells. NK cells may play a key role in maintaining immunologic tolerance at the maternal-fetal interface. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Natural killer cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monocytes and promonocytes are present in the fetal liver, but circulating monocytes remain rare until the bone marrow becomes the predominant site of hematopoiesis. Impaired monocyte function in neonates may be partially responsible for poorer cytokine responses of neonatal T cells and the diminished delayed-type hypersensitivity (DTH) skin test reactions seen before one year of age. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Monocytes and macrophages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasmacytoid dendritic cells (pDCs) are increased in number and proportion in cord blood compared with adult peripheral blood. Neonatal DCs have poorer antigen-presenting function and T cell activation than adult DCs. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Dendritic cells'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/1\">",
"      Holt PG, Jones CA. The development of the immune system during pregnancy and early life. Allergy 2000; 55:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/2\">",
"      Crompton T, Outram SV, Hager-Theodorides AL. Sonic hedgehog signalling in T-cell development and activation. Nat Rev Immunol 2007; 7:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/3\">",
"      Anderson G, Moore NC, Owen JJ, Jenkinson EJ. Cellular interactions in thymocyte development. Annu Rev Immunol 1996; 14:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/4\">",
"      Bodey B, Kaiser HE. Development of Hassall's bodies of the thymus in humans and other vertebrates (especially mammals) under physiological and pathological conditions: immunocytochemical, electronmicroscopic and in vitro observations. In Vivo 1997; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/5\">",
"      Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Novel insights into the function of the thymic Hassall's bodies. In Vivo 2000; 14:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/6\">",
"      Mathieson BJ, Fowlkes BJ. Cell surface antigen expression on thymocytes: development and phenotypic differentiation of intrathymic subsets. Immunol Rev 1984; 82:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/7\">",
"      Kraft DL, Weissman IL, Waller EK. Differentiation of CD3-4-8- human fetal thymocytes in vivo: characterization of a CD3-4+8- intermediate. J Exp Med 1993; 178:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/8\">",
"      Chidgey AP, Boyd RL. Thymic stromal cells and positive selection. APMIS 2001; 109:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/9\">",
"      Viret C, Janeway CA Jr. MHC and T cell development. Rev Immunogenet 1999; 1:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/10\">",
"      Haynes BF. The human thymic microenvironment. Adv Immunol 1984; 36:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/11\">",
"      George JF Jr, Schroeder HW Jr. Developmental regulation of D beta reading frame and junctional diversity in T cell receptor-beta transcripts from human thymus. J Immunol 1992; 148:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/12\">",
"      Teyton L, Apostolopoulos V, Cantu C 3rd, et al. Function and dysfunction of T cell receptor: structural studies. Immunol Res 2000; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/13\">",
"      Garcia KC, Degano M, Speir JA, Wilson IA. Emerging principles for T cell receptor recognition of antigen in cellular immunity. Rev Immunogenet 1999; 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/14\">",
"      Hazenberg MD, Verschuren MC, Hamann D, et al. T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation. J Mol Med (Berl) 2001; 79:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/15\">",
"      Jouvin-Marche E, Fuschiotti P, Marche PN. Dynamic aspects of TCRalpha gene recombination: qualitative and quantitative assessments of the TCRalpha chain repertoire in man and mouse. Adv Exp Med Biol 2009; 650:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/16\">",
"      Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/17\">",
"      Schelonka RL, Raaphorst FM, Infante D, et al. T cell receptor repertoire diversity and clonal expansion in human neonates. Pediatr Res 1998; 43:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/18\">",
"      Bonati A, Zanelli P, Ferrari S, et al. T-cell receptor beta-chain gene rearrangement and expression during human thymic ontogenesis. Blood 1992; 79:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/19\">",
"      Garderet L, Dulphy N, Douay C, et al. The umbilical cord blood alphabeta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood 1998; 91:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/20\">",
"      Zemlin M, Schelonka RL, Bauer K, Schroeder HW Jr. Regulation and chance in the ontogeny of B and T cell antigen receptor repertoires. Immunol Res 2002; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/21\">",
"      Erkeller-Yuksel FM, Deneys V, Yuksel B, et al. Age-related changes in human blood lymphocyte subpopulations. J Pediatr 1992; 120:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/22\">",
"      Panaro A, Amati A, di Loreto M, et al. Lymphocyte subpopulations in pediatric age. Definition of reference values by flow cytometry. Allergol Immunopathol (Madr) 1991; 19:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/23\">",
"      Gasparoni A, Ciardelli L, Avanzini A, et al. Age-related changes in intracellular TH1/TH2 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in newborns, children and adults. Biol Neonate 2003; 84:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/24\">",
"      Thilaganathan B, Mansur CA, Morgan G, Nicolaides KH. Fetal T-lymphocyte subpopulations in normal pregnancies. Fetal Diagn Ther 1992; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/25\">",
"      S&eacute;ri&egrave;s IM, Pichette J, Carrier C, et al. Quantitative analysis of T and B cell subsets in healthy and sick premature infants. Early Hum Dev 1991; 26:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/26\">",
"      Wilson M, Rosen FS, Schlossman SF, Reinherz EL. Ontogeny of human T and B lymphocytes during stressed and normal gestation: phenotypic analysis of umbilical cord lymphocytes from term and preterm infants. Clin Immunol Immunopathol 1985; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/27\">",
"      Pirenne H, Aujard Y, Eljaafari A, et al. Comparison of T cell functional changes during childhood with the ontogeny of CDw29 and CD45RA expression on CD4+ T cells. Pediatr Res 1992; 32:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/28\">",
"      Hassan J, Reen DJ. Neonatal CD4+ CD45RA+ T cells: precursors of adult CD4+ CD45RA+ T cells? Res Immunol 1993; 144:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/29\">",
"      Hoshino T, Yamada A, Honda J, et al. Tissue-specific distribution and age-dependent increase of human CD11b+ T cells. J Immunol 1993; 151:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/30\">",
"      Splawski JB, Jelinek DF, Lipsky PE. Delineation of the functional capacity of human neonatal lymphocytes. J Clin Invest 1991; 87:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/31\">",
"      Schaub B, Liu J, Schleich I, et al. Impairment of T helper and T regulatory cell responses at birth. Allergy 2008; 63:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/32\">",
"      Roncarolo MG, Bigler M, Ciuti E, et al. Immune responses by cord blood cells. Blood Cells 1994; 20:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/33\">",
"      Reen DJ, Early E. Cord blood 'naive' T cells demonstrate distinct immunological properties compared with their adult counterparts. Bone Marrow Transplant 1998; 22 Suppl 1:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/34\">",
"      Risdon G, Gaddy J, Stehman FB, Broxmeyer HE. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol 1994; 154:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/35\">",
"      Clerici M, DePalma L, Roilides E, et al. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages. J Clin Invest 1993; 91:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/36\">",
"      Liechty KW, Adzick NS, Crombleholme TM. Diminished interleukin 6 (IL-6) production during scarless human fetal wound repair. Cytokine 2000; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/37\">",
"      M&uuml;ller K, Zak M, Nielsen S, et al. In vitro cytokine production and phenotype expression by blood mononuclear cells from umbilical cords, children and adults. Pediatr Allergy Immunol 1996; 7:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/38\">",
"      Sautois B, Fillet G, Beguin Y. Comparative cytokine production by in vitro stimulated mononucleated cells from cord blood and adult blood. Exp Hematol 1997; 25:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/39\">",
"      Qian JX, Lee SM, Suen Y, et al. Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity and cytokine production in cord blood. Blood 1997; 90:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/40\">",
"      Lilic D, Cant AJ, Abinun M, et al. Cytokine production differs in children and adults. Pediatr Res 1997; 42:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/41\">",
"      Seghaye MC, Heyl W, Grabitz RG, et al. The production of pro- and anti-inflammatory cytokines in neonates assessed by stimulated whole cord blood culture and by plasma levels at birth. Biol Neonate 1998; 73:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/42\">",
"      Chheda S, Palkowetz KH, Garofalo R, et al. Decreased interleukin-10 production by neonatal monocytes and T cells: relationship to decreased production and expression of tumor necrosis factor-alpha and its receptors. Pediatr Res 1996; 40:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/43\">",
"      Chang M, Suen Y, Lee SM, et al. Transforming growth factor-beta 1, macrophage inflammatory protein-1 alpha, and interleukin-8 gene expression is lower in stimulated human neonatal compared with adult mononuclear cells. Blood 1994; 84:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/44\">",
"      Pirenne-Ansart H, Paillard F, De Groote D, et al. Defective cytokine expression but adult-type T-cell receptor, CD8, and p56lck modulation in CD3- or CD2-activated T cells from neonates. Pediatr Res 1995; 37:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/45\">",
"      Cairo MS, Suen Y, Knoppel E, et al. Decreased stimulated GM-CSF production and GM-CSF gene expression but normal numbers of GM-CSF receptors in human term newborns compared with adults. Pediatr Res 1991; 30:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/46\">",
"      White GP, Watt PM, Holt BJ, Holt PG. Differential patterns of methylation of the IFN-gamma promoter at CpG and non-CpG sites underlie differences in IFN-gamma gene expression between human neonatal and adult CD45RO- T cells. J Immunol 2002; 168:2820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/47\">",
"      Gromo G, Geller RL, Inverardi L, Bach FH. Signal requirements in the step-wise functional maturation of cytotoxic T lymphocytes. Nature 1987; 327:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/48\">",
"      Steele CR, Oppenheim DE, Hayday AC. Gamma(delta) T cells: non-classical ligands for non-classical cells. Curr Biol 2000; 10:R282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/49\">",
"      Beetz S, Wesch D, Marischen L, et al. Innate immune functions of human gammadelta T cells. Immunobiology 2008; 213:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/50\">",
"      McVay LD, Carding SR. Extrathymic origin of human gamma delta T cells during fetal development. J Immunol 1996; 157:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/51\">",
"      Holtmeier W, Pf&auml;nder M, Hennemann A, et al. The TCR-delta repertoire in normal human skin is restricted and distinct from the TCR-delta repertoire in the peripheral blood. J Invest Dermatol 2001; 116:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/52\">",
"      Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/53\">",
"      Adkins B. Peripheral CD4+ lymphocytes derived from fetal versus adult thymic precursors differ phenotypically and functionally. J Immunol 2003; 171:5157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/54\">",
"      Delespesse G, Yang LP, Ohshima Y, et al. Maturation of human neonatal CD4+ and CD8+ T lymphocytes into Th1/Th2 effectors. Vaccine 1998; 16:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/55\">",
"      Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/56\">",
"      Ivanov S, Bozinovski S, Bossios A, et al. Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am J Respir Cell Mol Biol 2007; 36:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/57\">",
"      Cosmi L, De Palma R, Santarlasci V, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 2008; 205:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/58\">",
"      Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/59\">",
"      Takahashi N, Imanishi K, Nishida H, Uchiyama T. Evidence for immunologic immaturity of cord blood T cells. Cord blood T cells are susceptible to tolerance induction to in vitro stimulation with a superantigen. J Immunol 1995; 155:5213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/60\">",
"      Toubert A, Douay C, Chalumeau N, et al. Effects of superantigenic stimulation on the cord blood alphabeta T cell repertoire. Bone Marrow Transplant 1998; 22 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/61\">",
"      Macardle PJ, Wheatland L, Zola H. Analysis of the cord blood T lymphocyte response to superantigen. Hum Immunol 1999; 60:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/62\">",
"      Liu CC, Young LH, Young JD. Lymphocyte-mediated cytolysis and disease. N Engl J Med 1996; 335:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/63\">",
"      K&auml;gi D, Ledermann B, B&uuml;rki K, et al. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 1996; 14:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/64\">",
"      Smyth MJ, Kelly JM, Sutton VR, et al. Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol 2001; 70:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/65\">",
"      Toivanen P, Uksila J, Leino A, et al. Development of mitogen responding T cells and natural killer cells in the human fetus. Immunol Rev 1981; 57:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/66\">",
"      Lubens RG, Gard SE, Soderberg-Warner M, Stiehm ER. Lectin-dependent T-lymphocyte and natural killer cytotoxic deficiencies in human newborns. Cell Immunol 1982; 74:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/67\">",
"      Peakman M, Buggins AG, Nicolaides KH, et al. Analysis of lymphocyte phenotypes in cord blood from early gestation fetuses. Clin Exp Immunol 1992; 90:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/68\">",
"      McVay LD, Carding SR. Generation of human gammadelta T-cell repertoires. Crit Rev Immunol 1999; 19:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/69\">",
"      Yamashita S, Tanaka Y, Harazaki M, et al. Recognition mechanism of non-peptide antigens by human gammadelta T cells. Int Immunol 2003; 15:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/70\">",
"      Hintz M, Reichenberg A, Altincicek B, et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Lett 2001; 509:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/71\">",
"      Morita CT, Parker CM, Brenner MB, Band H. TCR usage and functional capabilities of human gamma delta T cells at birth. J Immunol 1994; 153:3979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/72\">",
"      Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/73\">",
"      Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/74\">",
"      Barrat FJ, Cua DJ, Boonstra A, et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/75\">",
"      Darrasse-J&egrave;ze G, Marodon G, Salomon BL, et al. Ontogeny of CD4+CD25+ regulatory/suppressor T cells in human fetuses. Blood 2005; 105:4715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/76\">",
"      Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/77\">",
"      Allman D, Miller JP. Common lymphoid progenitors, early B-lineage precursors, and IL-7: characterizing the trophic and instructive signals underlying early B cell development. Immunol Res 2003; 27:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/78\">",
"      Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/79\">",
"      Klein M. Immunological markers of human mononuclear cells. Clin Biochem 1983; 16:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/80\">",
"      Nossal GJ. The Florey lecture, 1986. The regulatory biology of antibody formation. Proc R Soc Lond B Biol Sci 1986; 228:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/81\">",
"      Buhl AM, Nemazee D, Cambier JC, et al. B-cell antigen receptor competence regulates B-lymphocyte selection and survival. Immunol Rev 2000; 176:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/82\">",
"      Rudin CM, Thompson CB. B-cell development and maturation. Semin Oncol 1998; 25:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/83\">",
"      Pillai S, Cariappa A, Moran ST. Marginal zone B cells. Annu Rev Immunol 2005; 23:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/84\">",
"      Bofill M, Janossy G, Janossa M, et al. Human B cell development. II. Subpopulations in the human fetus. J Immunol 1985; 134:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/85\">",
"      Dorshkind K, Montecino-Rodriguez E. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol 2007; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/86\">",
"      Oltz EM. Regulation of antigen receptor gene assembly in lymphocytes. Immunol Res 2001; 23:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/87\">",
"      Kelsoe G. V(D)J hypermutation and receptor revision: coloring outside the lines. Curr Opin Immunol 1999; 11:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/88\">",
"      Neuberger MS, Di Noia JM, Beale RC, et al. Somatic hypermutation at A.T pairs: polymerase error versus dUTP incorporation. Nat Rev Immunol 2005; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/89\">",
"      Casali P, Schettino EW. Structure and function of natural antibodies. Curr Top Microbiol Immunol 1996; 210:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/90\">",
"      Schroeder HW Jr, Hillson JL, Perlmutter RM. Early restriction of the human antibody repertoire. Science 1987; 238:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/91\">",
"      Choi Y, Rickert MH, Ballow M, Greenberg SJ. Human IgH-V gene repertoire in neonatal cord blood, adult peripheral blood, and EBV-transformed cells. Ann N Y Acad Sci 1995; 764:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/92\">",
"      Ridings J, Nicholson IC, Goldsworthy W, et al. Somatic hypermutation of immunoglobulin genes in human neonates. Clin Exp Immunol 1997; 108:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/93\">",
"      Paloczi K. Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells. Leukemia 1999; 13 Suppl 1:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/94\">",
"      Ugazio AG, Marcioni AF, Astaldi A Jr, Burgio GR. Peripheral blood B lymphocytes in infancy and childhood. Acta Paediatr Scand 1974; 63:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/95\">",
"      Thomas RM, Linch DC. Identification of lymphocyte subsets in the newborn using a variety of monoclonal antibodies. Arch Dis Child 1983; 58:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/96\">",
"      Durandy A, Thuillier L, Forveille M, Fischer A. Phenotypic and functional characteristics of human newborns' B lymphocytes. J Immunol 1990; 144:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/97\">",
"      Johnson CC, Ownby DR, Peterson EL. Parental history of atopic disease and concentration of cord blood IgE. Clin Exp Allergy 1996; 26:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/98\">",
"      King CL, Malhotra I, Mungai P, et al. B cell sensitization to helminthic infection develops in utero in humans. J Immunol 1998; 160:3578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/99\">",
"      D'Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics 1995; 96:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/100\">",
"      Go��ebiowska M, Kardas-Sobantka D, Chlebna-Sok&oacute;�� D, Sabanty W. Hepatitis B vaccination in preterm infants. Eur J Pediatr 1999; 158:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/101\">",
"      Palfi M, Hild&eacute;n JO, Gottvall T, Selbing A. Placental transport of maternal immunoglobulin G in pregnancies at risk of Rh (D) hemolytic disease of the newborn. Am J Reprod Immunol 1998; 39:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/102\">",
"      Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986; 20:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/103\">",
"      Yeung CY, Hobbs JR. Serum-gamma-G-globulin levels in normal premature, post-mature, and \"small-for-dates\" newborn babies. Lancet 1968; 1:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/104\">",
"      Merbl Y, Zucker-Toledano M, Quintana FJ, Cohen IR. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007; 117:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/105\">",
"      Deorari AK, Broor S, Maitreyi RS, et al. Incidence, clinical spectrum, and outcome of intrauterine infections in neonates. J Trop Pediatr 2000; 46:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/106\">",
"      Karras JG, Wang Z, Huo L, et al. Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes. J Exp Med 1997; 185:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/107\">",
"      Hardy RR. B-1 B cell development. J Immunol 2006; 177:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/108\">",
"      Montecino-Rodriguez E, Dorshkind K. New perspectives in B-1 B cell development and function. Trends Immunol 2006; 27:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/109\">",
"      Kantor AB, Herzenberg LA. Origin of murine B cell lineages. Annu Rev Immunol 1993; 11:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/110\">",
"      Bhat NM, Kantor AB, Bieber MM, et al. The ontogeny and functional characteristics of human B-1 (CD5+ B) cells. Int Immunol 1992; 4:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/111\">",
"      Hardy RR, Hayakawa K. A developmental switch in B lymphopoiesis. Proc Natl Acad Sci U S A 1991; 88:11550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/112\">",
"      Alugupalli KR, Leong JM, Woodland RT, et al. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 2004; 21:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/113\">",
"      Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 2005; 23:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/114\">",
"      Bishop GA, Hostager BS. B lymphocyte activation by contact-mediated interactions with T lymphocytes. Curr Opin Immunol 2001; 13:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/115\">",
"      Nonoyama S, Etzioni A, Toru H, et al. Diminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency. Eur J Immunol 1998; 28:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/116\">",
"      Merrill JD, Sigaroudinia M, Kohl S. Characterization of natural killer and antibody-dependent cellular cytotoxicity of preterm infants against human immunodeficiency virus-infected cells. Pediatr Res 1996; 40:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/117\">",
"      Splawski JB, Nishioka J, Nishioka Y, Lipsky PE. CD40 ligand is expressed and functional on activated neonatal T cells. J Immunol 1996; 156:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/118\">",
"      Fehniger TA, Caligiuri MA. Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol 2001; 20:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/119\">",
"      Spits H, Blom B, Jaleco AC, et al. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev 1998; 165:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/120\">",
"      Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/121\">",
"      Volp&eacute; R. Graves' disease/model of SCID mouse. Exp Clin Endocrinol Diabetes 1996; 104 Suppl 3:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/122\">",
"      Phillips JH, Hori T, Nagler A, et al. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon,delta proteins. J Exp Med 1992; 175:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/123\">",
"      Gaddy J, Risdon G, Broxmeyer HE. Cord blood natural killer cells are functionally and phenotypically immature but readily respond to interleukin-2 and interleukin-12. J Interferon Cytokine Res 1995; 15:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/124\">",
"      Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/125\">",
"      Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 1997; 6:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/126\">",
"      Ortaldo JR, Winkler-Pickett RT, Nagashima K, et al. Direct evidence for release of pore-forming protein during NK cellular lysis. J Leukoc Biol 1992; 52:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/127\">",
"      Trinchieri G, Valiante N. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993; 12:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/128\">",
"      Gaunt G, Ramin K. Immunological tolerance of the human fetus. Am J Perinatol 2001; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/129\">",
"      Sato T, Laver JH, Aiba Y, Ogawa M. NK cell colony formation from human fetal thymocytes. Exp Hematol 1999; 27:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/130\">",
"      Middendorp S, Nieuwenhuis EE. NKT cells in mucosal immunity. Mucosal Immunol 2009; 2:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/131\">",
"      Takashina T. Haemopoiesis in the human yolk sac. J Anat 1987; 151:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/132\">",
"      Smythies LE, Maheshwari A, Clements R, et al. Mucosal IL-8 and TGF-beta recruit blood monocytes: evidence for cross-talk between the lamina propria stroma and myeloid cells. J Leukoc Biol 2006; 80:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/133\">",
"      Shepard JL, Zon LI. Developmental derivation of embryonic and adult macrophages. Curr Opin Hematol 2000; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/134\">",
"      Maheshwari A, Kurundkar AR, Shaik SS, et al. Epithelial cells in fetal intestine produce chemerin to recruit macrophages. Am J Physiol Gastrointest Liver Physiol 2009; 297:G1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/135\">",
"      Kelemen E, J&aacute;nossa M. Macrophages are the first differentiated blood cells formed in human embryonic liver. Exp Hematol 1980; 8:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/136\">",
"      Janossy G, Bofill M, Poulter LW, et al. Separate ontogeny of two macrophage-like accessory cell populations in the human fetus. J Immunol 1986; 136:4354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/137\">",
"      MacDonald TT, Weinel A, Spencer J. HLA-DR expression in human fetal intestinal epithelium. Gut 1988; 29:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/138\">",
"      Porcellini A, Manna A, Manna M, et al. Ontogeny of granulocyte-macrophage progenitor cells in the human fetus. Int J Cell Cloning 1983; 1:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/139\">",
"      Linch DC, Knott LJ, Rodeck CH, Huehns ER. Studies of circulating hemopoietic progenitor cells in human fetal blood. Blood 1982; 59:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/140\">",
"      Xanthou M. Leucocyte blood picture in healthy full-term and premature babies during neonatal period. Arch Dis Child 1970; 45:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/141\">",
"      Weinberg AG, Rosenfeld CR, Manroe BL, Browne R. Neonatal blood cell count in health and disease. II. Values for lymphocytes, monocytes, and eosinophils. J Pediatr 1985; 106:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/142\">",
"      Christensen RD, Jensen J, Maheshwari A, Henry E. Reference ranges for blood concentrations of eosinophils and monocytes during the neonatal period defined from over 63 000 records in a multihospital health-care system. J Perinatol 2010; 30:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/143\">",
"      Kurland G, Cheung AT, Miller ME, et al. The ontogeny of pulmonary defenses: alveolar macrophage function in neonatal and juvenile rhesus monkeys. Pediatr Res 1988; 23:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/144\">",
"      D'Ambola JB, Sherman MP, Tashkin DP, Gong H Jr. Human and rabbit newborn lung macrophages have reduced anti-Candida activity. Pediatr Res 1988; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/145\">",
"      Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/146\">",
"      Jaffe R. Review of human dendritic cells: isolation and culture from precursors. Pediatr Pathol 1993; 13:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/147\">",
"      Foster CA, Holbrook KA, Farr AG. Ontogeny of Langerhans cells in human embryonic and fetal skin: expression of HLA-DR and OKT-6 determinants. J Invest Dermatol 1986; 86:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/148\">",
"      Grouard G, Rissoan MC, Filgueira L, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/149\">",
"      O'Doherty U, Peng M, Gezelter S, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994; 82:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/150\">",
"      Velilla PA, Rugeles MT, Chougnet CA. Defective antigen-presenting cell function in human neonates. Clin Immunol 2006; 121:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/151\">",
"      Petty RE, Hunt DW. Neonatal dendritic cells. Vaccine 1998; 16:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/152\">",
"      Johnston RB Jr. Current concepts: immunology. Monocytes and macrophages. N Engl J Med 1988; 318:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/153\">",
"      Yoder MC, Lanker TA, Engle WA. Culture medium oxygen tension affects fibronectin production in human adult and cord blood macrophages. Immunol Lett 1988; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/154\">",
"      Stiehm ER, Sztein MB, Steeg PS, et al. Deficient DR antigen expression on human cord blood monocytes: reversal with lymphokines. Clin Immunol Immunopathol 1984; 30:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/155\">",
"      Bhoopat L, Taylor CR, Hofman FM. The differentiation antigens of macrophages in human fetal liver. Clin Immunol Immunopathol 1986; 41:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/156\">",
"      Weatherstone KB, Rich EA. Tumor necrosis factor/cachectin and interleukin-1 secretion by cord blood monocytes from premature and term neonates. Pediatr Res 1989; 25:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/157\">",
"      Wilson CB. Immunologic basis for increased susceptibility of the neonate to infection. J Pediatr 1986; 108:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/158\">",
"      Bessler H, Sirota L, Dulitzky F, Djaldetti M. Production of interleukin-1 by mononuclear cells of newborns and their mothers. Clin Exp Immunol 1987; 68:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/159\">",
"      Kesson AM, Bryson YJ. Induction of interferon-gamma by cord blood mononuclear cells is calcium dependent. Cell Immunol 1991; 133:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/160\">",
"      Kniker WT, Lesourd BM, McBryde JL, Corriel RN. Cell-mediated immunity assessed by Multitest CMI skin testing in infants and preschool children. Am J Dis Child 1985; 139:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/161\">",
"      Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol 2008; 181:3733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/162\">",
"      Schibler KR, Liechty KW, White WL, et al. Defective production of interleukin-6 by monocytes: a possible mechanism underlying several host defense deficiencies of neonates. Pediatr Res 1992; 31:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/163\">",
"      Schibler KR, Trautman MS, Liechty KW, et al. Diminished transcription of interleukin-8 by monocytes from preterm neonates. J Leukoc Biol 1993; 53:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/164\">",
"      Speer CP, Ambruso DR, Grimsley J, Johnston RB Jr. Oxidative metabolism in cord blood monocytes and monocyte-derived macrophages. Infect Immun 1985; 50:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/165\">",
"      Speer CP, Wieland M, Ulbrich R, Gahr M. Phagocytic activities in neonatal monocytes. Eur J Pediatr 1986; 145:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/166\">",
"      Weston WL, Carson BS, Barkin RM, et al. Monocyte-macrophage function in the newborn. Am J Dis Child 1977; 131:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?30/32/31242/abstract/167\">",
"      Bondada S, Wu H, Robertson DA, Chelvarajan RL. Accessory cell defect in unresponsiveness of neonates and aged to polysaccharide vaccines. Vaccine 2000; 19:557.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5950 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-677435A82C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31242=[""].join("\n");
var outline_f30_32_31242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6345244\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      T CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      T cell development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TCR repertoire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Circulating T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      T cell function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Proliferation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cytokine production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Antigen-specific responses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other T cell subgroups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cytotoxic T-lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gamma delta T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Regulatory T cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      B CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      B cell development",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Immunoglobulin repertoire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Circulating B cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      B cell function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Immunoglobulin production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serum immunoglobulin (Ig) concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other B cell subgroups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - B-1 cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      T AND B CELL INTERACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NATURAL KILLER CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NK cell development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      NK cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MONOCYTES AND MACROPHAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DENDRITIC CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DC development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DC function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      NEUTROPHILS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6345244\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5950\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5950|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/58/29613\" title=\"figure 1\">",
"      Thymocyte development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/42/30369\" title=\"figure 2\">",
"      T cell receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/10/41135\" title=\"figure 3\">",
"      Somatic recombination in TCR genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/4/8257\" title=\"figure 4\">",
"      Common precursors of lymphocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5950|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/58/1965\" title=\"table 1\">",
"      Salient differences",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25432?source=related_link\">",
"      Antigen presenting cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/12/16585?source=related_link\">",
"      Immunity of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37733?source=related_link\">",
"      T cell receptor genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_32_31243="Risks heart failure TZDs";
var content_f30_32_31243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for heart failure in patients treated with thiazolidinediones",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        1. History of heart failure (either systolic or diastolic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        2. History of prior myocardial infarction or symptomatic coronary artery disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        3. Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        4. Left ventricular hypertrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        5. Significant aortic or mitral valve heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        6. Advanced age (&gt;70 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        7. Long-standing diabetes (&gt;10 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        8. Preexisting edema or current treatment with loop diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        9. Development of edema or weight gain on TZD therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        10. Insulin coadministration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        11. Chronic renal failure (creatinine &gt;2.0 mg/dL)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108:2941. Copyright &copy; 2003 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31243=[""].join("\n");
var outline_f30_32_31243=null;
var title_f30_32_31244="Transverse recovery in MRI";
var content_f30_32_31244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rate of recovery during transverse relaxation in MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 228px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following 90&deg; radiofrequency relaxation, transverse magnetization is initially maximal and then decays exponentially due to dipolar interactions among spins (spin-spin relaxation) with a time contstant T2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31244=[""].join("\n");
var outline_f30_32_31244=null;
var title_f30_32_31245="Classification pediatric ILD";
var content_f30_32_31245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of pediatric interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Etiologic classification",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Primary pulmonary disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Alveolar hemorrhage syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aspiration syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Drug- or radiation-induced lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypersensitivity pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Infectious or postinfectious chronic lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lipid storage disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary alveolar proteinosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary infiltrates with eosinophilia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary vascular disorders (proliferative and congenital)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary lymphatic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary microlithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Systemic disorders with pulmonary involvement",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Connective tissue disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malignancies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Langerhans histiocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Neurocutaneous syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lipid storage disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Other inborn errors of metabolism (lysinuric protein intolerance)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Idiopathic interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Histologic pattern",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Usual interstitial pneumonitis (UIP)*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Desquamative interstitial pneumonitis (DIP)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lymphocytic interstitial pneumonitis (LIP) and related disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nonspecific interstitial pneumonitis (NSIP)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Organizing pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diffuse alveolar damage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Respiratory bronchiolitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Clinical, radiologic, pathologic diagnosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Idiopathic pulmonary fibrosis (IPF)/cryptogenic fibrosis alveolitis (CFA)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Desquamative interstitial pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lymphocytic interstitial pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nonspecific interstitial pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cryptogenic organizing pneumonia",
"            <sup>",
"             &bull;",
"            </sup>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acute interstitial pneumonia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Respiratory bronchiolitis interstitial lung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Unique forms of interstitial lung disease in infancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disorders of lung growth and development",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuroendocrine cell hyperplasia of infancy (NEHI)/persistent tachypnea of infancy (PTI)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Follicular bronchitis/broncholitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pulmonary interstitial glycogenosis/cellular interstitial pneumonitis of infancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute idiopathic pulmonary hemorrhage of infancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genetic defects of surfactant function/chronic pneumonitis of infancy",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Actual cases not reported in children.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Previously called bronchiolitis obliterans with organizing pneumonia (BOOP).",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fan LL, Deterding RR, Langston C. Pediatric interstitial lung disease revisited. Pediatr Pulmonol 2004; 38:369.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31245=[""].join("\n");
var outline_f30_32_31245=null;
var title_f30_32_31246="Enamel hypoplasia";
var content_f30_32_31246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enamel hypoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 212px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis J McTigue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31246=[""].join("\n");
var outline_f30_32_31246=null;
var title_f30_32_31247="Post-ERCP perforation";
var content_f30_32_31247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of a retroperitoneal duodenal perforation following biliary sphincterotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perforation site is visible above the bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Luigi Familiari, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_32_31247=[""].join("\n");
var outline_f30_32_31247=null;
